# 2025年12月23日 - 专业文献速递

本期速递为您整理了最新的科研文献及AI评价，每一篇文献都包含了详细的元数据、原文摘要、中文翻译和AI的专业点评，敬请参考。

---

## 1. 回复：关于在肝细胞癌肿瘤异质性解析中加入额外临床评分的建议

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/41428359)
**期刊：** Hepatology (Baltimore, Md.)
**PMID：** 41428359
**DOI：** 10.1097/HEP.0000000000001656

### 第一部分 原文与翻译

**英文原标题：** Reply: The suggestion for additional clinical scores in decoding tumor heterogeneity in HCC.

> **英文摘要：**
> No abstract available.

> **中文摘要：**
> 无可用摘要。

### 第二部分 AI 大师评价

该文为对肝细胞癌（HCC）中肿瘤异质性评估方法的学术回复，围绕是否应在现有分析框架中加入额外临床评分展开讨论。尽管缺乏摘要，但标题提示作者针对前期研究提出的评分体系进行了学术回应或方法补充。文章可能强调临床量化工具在解析肿瘤异质性方面的重要性，同时指出如何平衡模型复杂度与临床可操作性。整体上属于针对特定研究建议的简短学术交流，有助于深化HCC精准分层研究的讨论。

---

## 2. 致编辑的信：关于在解读肝细胞癌肿瘤异质性中增加临床评分的建议

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/41428351)
**期刊：** Hepatology (Baltimore, Md.)
**PMID：** 41428351
**DOI：** 10.1097/HEP.0000000000001655

### 第一部分 原文与翻译

**英文原标题：** Letter to the Editor: The suggestion for additional clinical scores in decoding tumor heterogeneity in HCC.

> **英文摘要：**
> No abstract available.

> **中文摘要：**
> 无摘要提供。

### 第二部分 AI 大师评价

本文为《肝脏病学》杂志的致编辑信，作者提出在解读肝细胞癌（HCC）肿瘤异质性时，增加或改进临床评分体系的建议。文章可能旨在促进更精确的患者分层和预后评估，以应对HCC复杂的分子与病理差异。尽管形式简短，但观点具有启发性，为临床与研究领域的跨维整合提供了参考方向。局限性在于缺乏实证数据支撑，尚需进一步验证其临床应用潜力。

---

## 3. 利用低通量全基因组亚硫酸氢盐测序检测RAS野生型转移性结直肠癌中ctDNA：VALENTINO试验的探索性目标。

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/41427962)
**期刊：** Clinical cancer research : an official journal of the American Association for Cancer Research
**PMID：** 41427962
**DOI：** 10.1158/1078-0432.CCR-25-2773

### 第一部分 原文与翻译

**英文原标题：** CtDNA detection with low-pass whole genome bisulfite sequencing in RAS wild-type metastatic colorectal cancer: an exploratory objective of the VALENTINO trial.

> **英文摘要：**
> PURPOSE: Longitudinal measuring of circulating tumor DNA (ctDNA) during systemic treatment of metastatic colorectal cancer (mCRC) is promising for disease monitoring, but it is hampered by high costs and lacks formal demonstration of clinical usefulness.
> 
> PATIENTS AND METHODS: We leveraged METER, a novel, highly reproducible, computational workflow that infers ctDNA presence and fraction from low-pass whole genome bisulfite sequencing to investigate baseline and 8-week ctDNA dynamics in patients with RAS wild-type mCRC undergoing first-line treatment with panitumumab/FOLFOX in the VALENTINO randomized phase 2 trial. IchorCNA was used to provide a benchmark for METER.
> 
> RESULTS: A total of 154 patients were evaluable. Baseline ctDNA was detected in 72.7% of patients and was associated with significantly higher risk of progression (1.65, 95%CI: 1.13-2.42; p=0.010) and death (HR: 2.24, 95%CI: 1.37-3.66; p<0.001). CtDNA clearance at 8 weeks was observed in 80.2% of patients with baseline detectable ctDNA; persistence of ctDNA was associated with significantly higher risk of progression (2.70, 95%CI: 1.63-4.49; p<0.001) and death (HR: 3.37, 95%CI: 2.00-5.69; p<0.001). CtDNA clearance was associated with a more profound depth of response (DoR) (median -48.4% vs -41.2%; p=0.023) but not with a higher frequency of early tumor shrinkage (72.0% vs 73.7%, p=1.00). METER expanded the number of ctDNA-positive patients relative to a copy number alteration- and a variant allele frequency-based methods.
> 
> CONCLUSION: CtDNA detection and quantification with METER is a promising tool for cost-effective treatment monitoring in mCRC and can complement radiological assessment of response dynamics.

> **中文摘要：**
> 目的：在转移性结直肠癌（mCRC）的全身治疗过程中进行循环肿瘤DNA（ctDNA）的纵向测量在疾病监测方面具有潜力，但受高成本及临床效用缺乏正式验证的限制。
> 
> 患者与方法：我们采用METER这一新颖、高度可重复的计算流程，从低通量全基因组亚硫酸氢盐测序数据推断ctDNA的存在及比例，以研究在VALENTINO随机Ⅱ期试验中接受帕尼单抗/FOLFOX一线治疗的RAS野生型mCRC患者的基线及8周ctDNA动态变化。使用IchorCNA作为METER的对照基准。
> 
> 结果：共有154名患者可评估。在基线时，72.7%的患者检测到ctDNA，其与疾病进展风险显著增加（HR=1.65，95%CI：1.13-2.42；p=0.010）及死亡风险升高（HR=2.24，95%CI：1.37-3.66；p<0.001）相关。在基线可检测ctDNA的患者中，8周时80.2%观察到ctDNA清除；ctDNA持续存在与显著更高的疾病进展风险（HR=2.70，95%CI：1.63-4.49；p<0.001）及死亡风险（HR=3.37，95%CI：2.00-5.69；p<0.001）相关。ctDNA清除与更深的应答深度（DoR）（中位数-48.4% vs -41.2%；p=0.023）相关，但与早期肿瘤缩小频率（72.0% vs 73.7%，p=1.00）无关。与基于拷贝数变异和变异等位基因频率的方法相比，METER扩大了ctDNA阳性患者的检测数量。
> 
> 结论：通过METER进行ctDNA检测与定量是一种具有成本效益的mCRC治疗监测工具，并可补充影像学对应答动态的评估。

### 第二部分 AI 大师评价

本研究旨在评估一种基于低通量全基因组亚硫酸氢盐测序的新型计算流程METER在检测RAS野生型转移性结直肠癌患者ctDNA中的可行性与临床意义。研究结果显示，基线ctDNA阳性及治疗8周后ctDNA持续存在的患者在疾病进展与总体生存方面均表现出显著较差的预后。METER方法不仅提高了ctDNA检出率，还能有效反映治疗应答深度。该研究为ctDNA在mCRC监测中的应用提供了经济高效的新途径，但仍需进一步验证其在不同临床环境下的普适性与临床决策价值。

---

## 4. AURORA 项目（BIG 14-01）中基因融合的分子与临床分析揭示原发性与转移性乳腺癌中的潜在治疗靶点

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/41427961)
**期刊：** Clinical cancer research : an official journal of the American Association for Cancer Research
**PMID：** 41427961
**DOI：** 10.1158/1078-0432.CCR-25-2707

### 第一部分 原文与翻译

**英文原标题：** Molecular and clinical analyses of gene fusions identify therapeutic targets in paired primary and metastatic breast cancer from the AURORA program (BIG 14-01).

> **英文摘要：**
> PURPOSE: Gene fusions are molecular rearrangements with oncogenic potential. However, their role in disease progression and therapy resistance remains largely unexplored, particularly in breast cancer.
> 
> EXPERIMENTAL DESIGN: In this study, we utilized multi-omics data from the AURORA program to characterize gene fusions in metastatic breast cancer. We analyzed RNA sequencing data from 325 primary tumors and 350 metastatic lesions across 476 patients to develop a high-confidence catalog of gene fusions.
> 
> RESULTS: In a subset of 398 matched samples from 199 patients, we observed a higher burden of gene fusions in metastatic tumors compared to their corresponding primary tumors. Metastatic-specific (acquired) gene fusions were characterized by few recurrent rearrangements and were generally absent in patients with de novo metastatic disease. We observed a colocalization of gene fusions with subtype-specific copy-number gains. Various scores indicative of genomic instability were found to be associated with the gene fusion burden. Fusions involving genes located within the same topologically associating domain (TAD) were common in HER2-positive tumors and frequently acquired in metastatic triple-negative breast cancer. The presence of gene fusions, particularly those that were acquired or involved genes within the same TAD, was associated with poor prognosis in ER-positive/HER2-negative tumors. Patients with acquired ESR1 fusions exhibited a more aggressive disease course, characterized by shorter treatment response and poorer clinical outcomes.
> 
> CONCLUSIONS: The AURORA gene fusion catalog may serve as a valuable resource for identifying targetable genetic alterations, thereby supporting the development of more effective therapeutic strategies for breast cancer.

> **中文摘要：**
> 研究目的：基因融合是一类具有致瘤潜能的分子重排。然而，它们在疾病进展和治疗耐受中的作用仍 largely 未被探索，尤其是在乳腺癌中。
> 
> 实验设计：在本研究中，我们利用 AURORA 项目的多组学数据对转移性乳腺癌中的基因融合进行了特征化分析。我们分析了来自 476 名患者的 325 个原发肿瘤和 350 个转移病灶的 RNA 测序数据，以建立一个高置信度的基因融合目录。
> 
> 研究结果：在来自 199 名患者的 398 对匹配样本中，我们观察到转移性肿瘤的基因融合负担高于其相应的原发肿瘤。转移特异性（获得性）基因融合表现为较少的复发性重排，并且通常不存在于原发即为转移性疾病的患者中。我们观察到基因融合与亚型特异性的拷贝数增加存在共定位关系。多种代表基因组不稳定性的评分与基因融合负担相关。涉及位于同一拓扑关联域（TAD）内基因的融合在 HER2 阳性肿瘤中常见，并在转移性三阴性乳腺癌中频繁获得。基因融合的存在，尤其是获得性基因融合或涉及同一 TAD 内基因的融合，与 ER 阳性 / HER2 阴性肿瘤的不良预后相关。携带获得性 ESR1 融合的患者表现出更具侵袭性的疾病进展过程，其特征为更短的治疗反应时间和较差的临床结局。
> 
> 研究结论：AURORA 基因融合目录可作为鉴定可靶向基因改变的有价值资源，从而支持更有效乳腺癌治疗策略的开发。

### 第二部分 AI 大师评价

本研究系统性地利用 AURORA 项目的多组学数据，揭示转移性乳腺癌中基因融合的分子特征及其临床意义。研究发现，转移灶具有更高的融合基因负担，与基因组不稳定性和肿瘤亚型密切相关。尤其是获得性融合及位于同一 TAD 内的融合，与不良预后显著关联。该工作为靶向乳腺癌基因融合提供了宝贵资源和潜在治疗靶点，但其因样本类型和异质性限制，仍需进一步验证机制与临床可操作性。

---

## 5. Capivasertib（AZD5363）这款强效口服的全AKT抑制剂在复发或难治性B细胞非霍奇金淋巴瘤（CAPITAL研究）患者中的疗效与安全性研究

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/41427952)
**期刊：** Clinical cancer research : an official journal of the American Association for Cancer Research
**PMID：** 41427952
**DOI：** 10.1158/1078-0432.CCR-25-2239

### 第一部分 原文与翻译

**英文原标题：** Efficacy and Safety of Capivasertib (AZD5363), a Potent, Oral Pan-AKT Inhibitor, in Patients with Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma (CAPITAL).

> **英文摘要：**
> PURPOSE: An unmet treatment need remains for relapsed/refractory (R/R) non-Hodgkin lymphoma (NHL), including the follicular lymphoma (FL), mantle cell lymphoma (MCL), and marginal zone lymphoma (MZL) subtypes. The PI3K/AKT/mTOR pathway is dysregulated and associated with poor prognosis in NHL. The AKT inhibitor capivasertib has preclinical activity in hematologic malignancy models.
> 
> METHODS: NCT05008055 was a modular, open-label, multicenter phase II study that examined oral capivasertib monotherapy in patients with R/R B-cell NHL who had received ≥2 prior lines of therapy. Patients had R/R FL (Cohort 1A), MZL (Cohort 1B), or MCL (Cohort 1C). Capivasertib 480 mg twice daily was administered orally 4 days on/3 days off. The primary objective was to determine the objective response rate (ORR) by blinded independent central review.
> 
> RESULTS: 30 patients were enrolled (of 272 planned). The ORRs for patients with R/R FL, MZL, and MCL were 18.8% (3/16), 33.3% (1/3), and 30% (3/10), respectively; 62.5% (10/16) of patients with R/R FL had stable disease. Baseline tumor PTEN expression was deficient/undetectable in the two patients who had a complete response and three of five patients who had a partial response. The most common capivasertib-related adverse events (AEs) were diarrhea (63.3%), nausea (20%), vomiting (13.3%), and hyperglycemia (10%). Capivasertib-related grade ≥3 AEs or serious AEs were observed in 9 and 3 patients, respectively.
> 
> CONCLUSION: The study was terminated early with a small sample size, limiting interpretation, although antitumor activity was limited. Future studies of capivasertib in hematologic malignancies would likely require biomarker-directed patient selection and/or combination therapy.

> **中文摘要：**
> 研究目的：复发/难治性（R/R）非霍奇金淋巴瘤（NHL），包括滤泡性淋巴瘤（FL）、套细胞淋巴瘤（MCL）和边缘区淋巴瘤（MZL）亚型，在治疗上仍存在未满足的需求。PI3K/AKT/mTOR通路在NHL中存在失调，并与不良预后相关。AKT抑制剂capivasertib在血液系统恶性肿瘤模型中表现出前临床活性。
> 
> 研究方法：NCT05008055是一项模块化、开放标签、多中心的II期研究，评估口服capivasertib单药治疗已接受过≥2线既往治疗的R/R B细胞NHL患者的效果。患者包括R/R FL（队列1A）、MZL（队列1B）或MCL（队列1C）。Capivasertib以480毫克口服，每日两次，连续服药4天后停药3天。主要研究目标是由盲法独立中央评审确定的客观缓解率（ORR）。
> 
> 研究结果：共入组30例患者（计划272例）。R/R FL、MZL及MCL患者的ORR分别为18.8%（3/16）、33.3%（1/3）和30%（3/10）；此外，62.5%（10/16）的R/R FL患者病情稳定。在两例完全缓解患者及五例部分缓解患者中的三例中，基线肿瘤PTEN表达缺乏或不可检测。与capivasertib相关的最常见不良事件（AEs）为腹泻（63.3%）、恶心（20%）、呕吐（13.3%）及高血糖（10%）。与capivasertib相关的≥3级或严重AEs分别发生于9例和3例患者中。
> 
> 研究结论：由于样本量较小，该研究提前终止，结果解释受到限制，且抗肿瘤活性有限。未来在血液系统恶性肿瘤中研究capivasertib时，可能需要采用生物标志物导向的患者筛选和/或联合治疗策略。

### 第二部分 AI 大师评价

该研究旨在探索AKT抑制剂capivasertib在复发或难治性B细胞非霍奇金淋巴瘤患者中的单药疗效与安全性。研究设计为开放性多中心II期试验，但由于入组不足，结果具有一定局限性。尽管观察到部分患者出现客观缓解和疾病稳定，但总体抗肿瘤活性有限。研究提示PTEN缺失可能与疗效相关，强调未来研究应结合分子标志物筛选或联合治疗以提高疗效。

---

## 6. INDUCE-3：一项针对复发性或转移性头颈部鳞状细胞癌患者的一线治疗随机Ⅱ/Ⅲ期研究，评估feladilimab联合pembrolizumab的疗效。

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/41427951)
**期刊：** Clinical cancer research : an official journal of the American Association for Cancer Research
**PMID：** 41427951
**DOI：** 10.1158/1078-0432.CCR-25-1197

### 第一部分 原文与翻译

**英文原标题：** INDUCE-3: A randomized Phase II/III study of first-line feladilimab plus pembrolizumab in patients with recurrent/metastatic head and neck squamous cell carcinoma.

> **英文摘要：**
> PURPOSE: Feladilimab, an inducible T-cell co‑stimulatory receptor agonist, demonstrated clinical activity in combination with pembrolizumab in a Phase I head and neck squamous cell carcinoma (HNSCC) expansion cohort, prompting further evaluation in patients in this setting.
> 
> PATIENTS AND METHODS: INDUCE-3 (NCT04128696) was a randomized, double-blind, Phase II/III study in first-line programmed death-ligand 1-positive recurrent and/or metastatic HNSCC patients. A 2-in-1 adaptive design was implemented, with an option to expand the Phase II study into a Phase III confirmatory study. Patients were randomized 1:1 to receive feladilimab plus pembrolizumab or placebo plus pembrolizumab; up to 35 cycles of treatment for approximately 2 years. Primary endpoints were overall survival (OS) and investigator-assessed progression-free survival (PFS).
> 
> RESULTS: The study enrolled 315 patients. Following review of unblinded interim data in 140 patients, an Independent Data Monitoring Committee recommended stopping patient accrual based on prespecified criteria. Existing patients discontinued feladilimab or placebo. Pembrolizumab treatment continued until prespecified stopping criteria were met. This study demonstrated no evidence of an effect in favor of feladilimab plus pembrolizumab, with an adjusted HR of 1.51 for OS and 1.40 for PFS (median OS: 44.1 weeks [95% confidence interval (CI): 35.9-NA]; median PFS: 10.1 weeks [95% CI: 9.1-15.0]) versus placebo plus pembrolizumab (median OS: not reached; median PFS: 16.0 weeks [95% CI: 14.3-26.1]). The incidence of treatment-related adverse events was higher in the placebo group.
> 
> CONCLUSIONS: This analysis does not support the combination of feladilimab plus pembrolizumab due to lack of superiority over placebo plus pembrolizumab.

> **中文摘要：**
> 研究目的：Feladilimab是一种可诱导型T细胞共刺激受体激动剂，在Ⅰ期头颈部鳞状细胞癌（HNSCC）扩展队列中联合pembrolizumab显示出临床活性，这促使进一步在该人群中进行研究。
> 
> 患者与方法：INDUCE-3（NCT04128696）是一项随机、双盲的Ⅱ/Ⅲ期研究，纳入复发和/或转移性、PD‑L1阳性的HNSCC患者，接受一线治疗。研究采用“二合一”自适应设计，可将Ⅱ期研究扩展为Ⅲ期验证性研究。患者按1:1比例随机分配接受feladilimab联合pembrolizumab或安慰剂联合pembrolizumab治疗；治疗最长达约2年，共35个周期。主要终点为总生存期（OS）和研究者评估的无进展生存期（PFS）。
> 
> 研究结果：共入组315例患者。在对140例患者的非盲中期数据进行审查后，独立数据监查委员会根据预设标准建议停止入组。现有患者停止使用feladilimab或安慰剂，pembrolizumab治疗继续至达到预设终止标准。研究未显示feladilimab联合pembrolizumab相较安慰剂联合pembrolizumab具有优势，调整后的OS风险比为1.51，PFS风险比为1.40（中位OS：44.1周[95%置信区间(CI)：35.9‑NA]；中位PFS：10.1周[95% CI：9.1‑15.0]），而安慰剂组的中位OS尚未达到，中位PFS为16.0周[95% CI：14.3‑26.1]。与治疗相关的不良事件发生率在安慰剂组更高。
> 
> 结论：由于feladilimab联合pembrolizumab相较安慰剂联合pembrolizumab未显示出优越性，本分析不支持该联合方案的进一步应用。

### 第二部分 AI 大师评价

该研究为一项随机、双盲的Ⅱ/Ⅲ期临床试验，评估feladilimab联合pembrolizumab在复发或转移性头颈部鳞状细胞癌一线治疗中的疗效。结果显示，该联合方案在总生存期和无进展生存期方面均未优于pembrolizumab单药。尽管feladilimab作为新型T细胞共刺激受体激动剂具有理论免疫增强潜力，但本研究未能验证其临床获益。研究设计严谨，但样本量扩大前即中止，可能影响最终结论的稳健性。

---

## 7. 抗体偶联药物在实体瘤疗效中的预测性生物标志物：当前挑战与定量蛋白质组学的潜在作用

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/41427810)
**期刊：** Clinical cancer research : an official journal of the American Association for Cancer Research
**PMID：** 41427810
**DOI：** 10.1158/1078-0432.CCR-25-3103

### 第一部分 原文与翻译

**英文原标题：** Predictive Biomarkers of Antibody-Drug Conjugate Efficacy for Solid Tumors: Current Challenges and the Potential Role of Quantitative Proteomics.

> **英文摘要：**
> Antibody-drug conjugate (ADC) development is progressing rapidly with significant impacts on the treatment landscape of clinical oncology. However, the development of predictive biomarkers to guide ADC selection has not kept pace, and to date has been mostly limited to immunohistochemistry, hampering patient selection and personalized treatment recommendations. Here, we review the current state of ADC target protein assessment, and the association between target expression levels and therapeutic efficacy. We discuss the limitations and challenges of existing protein assessment technology and highlight the potential clinical role of quantitative mass spectrometry-based proteomics for rapid, comprehensive and accurate protein quantification. We propose that integrating multiplexed proteomic assays early in ADC development and clinical trial design can improve therapeutic targeting, enhance clinical trial design and ultimately lead to more personalized ADC-based treatment strategies.

> **中文摘要：**
> 抗体偶联药物（ADC）的研发正在迅速推进，对临床肿瘤学的治疗格局产生了重大影响。然而，用于指导ADC选择的预测性生物标志物开发并未同步进行，迄今为止仍主要局限于免疫组织化学，这限制了患者筛选和个体化治疗推荐。本文回顾了当前ADC靶蛋白评估的现状，以及靶标表达水平与治疗疗效之间的关系。我们讨论了现有蛋白评估技术的局限性与挑战，并强调了基于定量质谱的蛋白质组学在实现快速、全面且精确的蛋白定量中的潜在临床作用。我们提出，在ADC研发及临床试验设计的早期阶段整合多重蛋白质组学检测，可改善治疗靶向性，优化临床试验设计，最终促进更加个体化的ADC治疗策略形成。

### 第二部分 AI 大师评价

该研究聚焦于抗体偶联药物在实体瘤治疗中的预测性生物标志物开发，指出现有主要依赖免疫组织化学的方法存在局限。作者提出将基于定量质谱的蛋白质组学应用于靶点评估，可实现更快速、全面和准确的蛋白定量。其创新在于引入多重蛋白质检测以优化ADC开发与临床试验设计，从而促进治疗个体化。尽管文章为方法学综述，未提供直接实验数据，但对未来ADC精准治疗策略具有重要启发意义。

---

## 8. Afadin缺失小鼠视网膜表现出严重的神经分层缺陷，但视觉功能仍得以保留。

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/41424252)
**期刊：** eLife
**PMID：** 41424252
**DOI：** 10.7554/eLife.105627

### 第一部分 原文与翻译

**英文原标题：** Afadin-deficient mouse retinas exhibit severe neuronal lamination defects but preserve visual functions.

> **英文摘要：**
> Neural lamination is a common feature of the CNS, with several subcellular structures, such as adherens junctions (AJs), playing a role in this process. The retina is also heavily laminated, but it remains unclear how laminar formation impacts retinal cell morphology, synapse integrity, and overall retinal function. In this study, we demonstrate that the loss of afadin, a key component of AJs, in mice leads to significant pathological changes. These include the disruption of outer retinal lamination and a notable decrease as well as mislocalization of photoreceptors, their outer segments, and photoreceptor synapses. Interestingly, despite these severe impairments, we recorded small local field potentials, including the a- and b-waves. We also classified retinal ganglion cells (RGCs) into ON, ON-OFF, and OFF types based on their firing patterns in response to light stimuli. Additionally, we successfully characterized the receptive fields of certain RGCs. Overall, these findings provide evidence that retinal circuit function can be partially preserved even when there are significant disruptions in both retinal lamination and photoreceptor synapses. Our results indicate that retinas with severely altered morphology still retain some capacity to process light stimuli.

> **中文摘要：**
> 神经分层是中枢神经系统的常见特征，多个亚细胞结构（如黏着连接，adherens junctions，AJs）在这一过程中发挥作用。视网膜同样具有显著的分层结构，但层状形成如何影响视网膜细胞形态、突触完整性及整体功能仍不清楚。本研究表明，在小鼠中丧失AJs关键成分afadin会导致显著的病理性变化，包括外层视网膜分层被破坏、光感受器数量明显减少及其外段和光感受器突触位点的错位。值得注意的是，尽管存在这些严重损害，我们仍记录到局部场电位的小幅信号，包括a波和b波。此外，我们根据视网膜神经节细胞（RGC）对光刺激的放电模式，将其分为ON型、ON-OFF型和OFF型。我们还成功地描绘了部分RGC的感受野。总体而言，这些发现提示，即使在视网膜分层和光感受器突触均受到显著破坏的情况下，视网膜神经环路的功能仍可部分保留。我们的结果表明，即便视网膜形态严重异常，其仍具备一定的光刺激处理能力。

### 第二部分 AI 大师评价

该研究以小鼠为模型，探讨了AJs关键蛋白afadin缺失对视网膜发育及功能的影响。研究者通过形态学及电生理分析发现，虽然视网膜层次结构严重紊乱、光感受器定位异常，但部分视觉信号传导仍得以保留，提示神经网络具备一定功能韧性。方法上整合了细胞组织学与功能性测量，结果兼具结构与功能层面的意义。创新之处在于揭示了分层结构破坏下视网膜仍可维持部分感光功能，局限性可能在于小鼠模型尚需进一步验证其与人类视觉系统的相关性。

---

## 9. 原发性腹膜后肉瘤术前活检与手术标本之间的组织学与恶性分级准确性：来自前瞻性腹膜后肉瘤登记研究（ReSAR）

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/41423753)
**期刊：** Annals of surgery
**PMID：** 41423753
**DOI：** 10.1097/SLA.0000000000007001

### 第一部分 原文与翻译

**英文原标题：** Accuracy of Histology and Malignancy Grade between Preoperative Biopsy and Surgical Specimens in Primary Retroperitoneal Sarcoma. A Study from the Prospective Retroperitoneal Sarcoma Registry (Resar).

> **英文摘要：**
> OBJECTIVE: This study aimed to prospectively assess the accuracy of preoperative biopsy in primary retroperitoneal sarcoma (RPS) across sarcoma referral centers.
> 
> SUMMARY BACKGROUND DATA: Histological subtype and malignancy grade are key for guiding RPS treatment strategies. However, the accuracy of preoperative biopsy remains uncertain.
> 
> METHODS: Data on adult patients with primary localized RPS who underwent preoperative biopsy followed by curative-intent surgery (2017-2020) were collected from the Retroperitoneal Sarcoma Registry. The study aimed to assess concordance between biopsy and surgical specimen histology and grade, using Cohen's kappa statistic. Concordance was also analyzed by center volume (high ≥13 vs. low <13 cases/year).
> 
> RESULTS: Of 894 enrolled patients, histologic concordance was observed in 87.7% of cases (unweighted κ=0.814; 95% CI, 0.773-0.854). Among 172 tumors initially diagnosed as well-differentiated liposarcomas, 44 (25.6%) were reclassified as dedifferentiated liposarcomas. Grade concordance was observed in 232 of 346 cases (76.1%; weighted κ=0.652; 95% CI, 0.589-0.715), with no difference between computed tomography- and ultrasound-guided biopsies. Concordance by tumor grade was 98.9% (grade 1), 62.1% (grade 2), and 40.2% (grade 3). In dedifferentiated liposarcomas, grade concordance was 59.7% (weighted κ=0.385; 95% CI, 0.292-0.479). High-volume centers showed higher concordance for both histology (κ=0.780) and grade (κ=0.680) compared with low-volume centers (κ=0.622 and 0.564, respectively).
> 
> CONCLUSIONS: While preoperative biopsy for RPS provides satisfactory histologic accuracy, tumor grade is frequently underestimated. This diagnostic inaccuracy may impact treatment decisions, particularly regarding preoperative therapies. Incorporating additional diagnostic factors may improve the accuracy of preoperative assessment.

> **中文摘要：**
> 研究目的：本研究旨在前瞻性评估各肉瘤转诊中心对原发性腹膜后肉瘤（RPS）术前活检的准确性。
> 
> 背景资料：组织学亚型和恶性程度分级是指导RPS治疗策略的关键因素。然而，术前活检的准确性仍不明确。
> 
> 研究方法：从腹膜后肉瘤登记数据库收集2017至2020年间接受术前活检并随后实施根治性手术的原发性局部RPS成年患者的数据。研究使用Cohen’s κ统计量评估活检与手术标本在组织学类型及分级上的一致性，同时根据中心病例量（高量中心≥13例/年 vs. 低量中心<13例/年）进行分层分析。
> 
> 结果：在894例入组患者中，组织学一致性为87.7%（未加权κ=0.814；95%置信区间：0.773–0.854）。在最初诊断为高分化型脂肪肉瘤的172个肿瘤中，有44例（25.6%）被重新分类为去分化型脂肪肉瘤。分级一致性在346例中有232例（76.1%；加权κ=0.652；95%置信区间：0.589–0.715），CT引导和超声引导活检之间无差异。按肿瘤分级的一致性分别为：1级98.9%、2级62.1%、3级40.2%。在去分化型脂肪肉瘤中，分级一致性为59.7%（加权κ=0.385；95%置信区间：0.292–0.479）。高量中心在组织学（κ=0.780）和分级（κ=0.680）的一致性均优于低量中心（分别为κ=0.622和0.564）。
> 
> 结论：尽管RPS术前活检在组织学诊断上具有较高准确性，但肿瘤等级常被低估。这种诊断不准确可能影响临床决策，尤其是涉及术前治疗的情况。纳入更多诊断因素可能有助于提升术前评估的精确度。

### 第二部分 AI 大师评价

该研究基于大规模前瞻性登记数据，系统评估了原发性腹膜后肉瘤术前活检与手术标本之间在组织学类型与恶性分级上的一致性。结果表明，组织学诊断的准确性较高，但恶性分级常被低估，尤其在去分化型脂肪肉瘤中更明显。高病例量中心在诊断一致性上表现更优。研究凸显了术前活检在疾病分层与治疗决策中的价值与局限性，为优化诊断流程及提高术前评估精准度提供了重要参考。

---

## 10. 曲古抑菌素A（TSA）在调控结直肠癌（CRC）患者淋巴细胞表观遗传修饰中的作用

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/41423678)
**期刊：** Clinical epigenetics
**PMID：** 41423678
**DOI：** 10.1186/s13148-025-01949-2

### 第一部分 原文与翻译

**英文原标题：** Role of Trichostatin A (TSA) in modulating the epigenetic modification in the lymphocytes of colorectal cancer (CRC).

> **英文摘要：**
> Trichostatin A (TSA) is a strong epigenetic tool that promises to have the future in the field of immune reprogramming, but its mechanisms of action in patient-derived immune cells in colorectal cancer (CRC) are still poorly studied. We examined in this current study the molecular and functional immune phenotype of lymphocytes of CRC patients and healthy donors in response to low-dose (0.1 nM), short-term (12 h) treatment with TSA, which aims at narrowing cytotoxicity and retaining epigenetic regulation. The TSA potentiated pro-inflammatory cytokines (IFN-gamma, IL-12, TNF-alpha) and inhibited immunoregulatory interleukins (IL-4, IL-10, IL-17, CCL5, Granzyme B in CRC-derived immune cells). At the transcriptional level, TSA induced TBX21 and TP53 and repressed GATA3, FOXP3, RORC, and MYC. Epigenetic profiling showed H3K14ac and H3K4me3 markups, H3K27me3 and HDAC1 downregulation, promoter hypermethylation of immune territory, less R-loop formation, and higher methylation of m6A RNA-partaking in the recommendation that TSA promotes chromatin and transcriptome multilayered modification. The TSA pretreated lymphocytes elicited cytotoxic effect in HT-29 CRC cells and also showed redox disproportion via depletion of glutathione and increase in nitric oxide. Although previous research focuses on the direct impact of TSA on tumor cells, in our study, we exclusively highlight TSA ability to reprogram the immune cells epigenetically in a more inflammatory tumor-reactive phenotype. The findings justify the possibility of TSA as an epigenetic adjunct of low toxicity in immuno-oncology and form a basis to continue in vivo and translational study in CRC immunotherapy.

> **中文摘要：**
> 曲古抑菌素A（TSA）是一种具有强大效能的表观遗传学工具，显示出在免疫重编程领域的应用前景，但其在结直肠癌（CRC）患者来源免疫细胞中的作用机制仍研究不足。本研究探讨了CRC患者及健康供体的淋巴细胞在低剂量（0.1 nM）、短时间（12小时）TSA处理下的分子及功能性免疫表型，旨在降低细胞毒性并保持表观遗传调控。TSA增强了促炎性细胞因子（IFN-γ、IL-12、TNF-α）的表达，同时抑制了CRC来源免疫细胞中免疫调节性白细胞介素（IL-4、IL-10、IL-17、CCL5、颗粒酶B）。在转录水平上，TSA诱导TBX21和TP53的表达，并抑制GATA3、FOXP3、RORC和MYC的转录。表观遗传分析显示，TSA上调H3K14ac和H3K4me3修饰，下调H3K27me3与HDAC1表达，促进免疫相关启动子区域高甲基化，减少R-loop形成，并提高m6A RNA甲基化水平，提示TSA推动染色质及转录组的多层次重塑。经TSA预处理的淋巴细胞对HT-29 CRC细胞表现出细胞毒效应，并通过谷胱甘肽耗竭和一氧化氮增加而引起氧化还原失衡。尽管以往研究多集中于TSA对肿瘤细胞的直接作用，我们的研究独特地强调了TSA通过表观遗传机制对免疫细胞进行重编程，使其呈现更具炎性和抗肿瘤反应的表型。研究结果支持TSA作为一种低毒性的表观遗传辅助剂在免疫肿瘤学中的应用潜力，并为进一步体内及转化性研究奠定基础。

### 第二部分 AI 大师评价

该研究以结直肠癌患者免疫细胞为模型，探索了曲古抑菌素A对淋巴细胞表观遗传调控及免疫表型的影响。研究通过低剂量、短时间处理策略，揭示TSA可增强促炎因子表达、抑制免疫抑制性因子，并诱导染色质多层表观修饰。结果表明TSA不仅作用于肿瘤细胞，也能通过重编程免疫细胞提升抗肿瘤活性。这为TSA作为免疫肿瘤治疗的表观遗传辅助药物提供了新思路，但仍需进一步体内验证其安全性与临床可行性。

---

## 11. 新辅助赛普利利单抗联合化疗用于可切除的食管鳞状细胞癌：一项单臂、Ⅱ期临床试验

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/41423619)
**期刊：** Nature communications
**PMID：** 41423619
**DOI：** 10.1038/s41467-025-67589-5

### 第一部分 原文与翻译

**英文原标题：** Neoadjuvant serplulimab combined with chemotherapy for resectable oesophageal squamous cell carcinoma: a single-arm, phase 2 trial.

> **英文摘要：**
> In this phase 2 trial, patients diagnosed with locally advanced oesophageal squamous cell carcinoma underwent three cycles of neoadjuvant therapy comprising serplulimab, carboplatin, and albumin paclitaxel. The primary endpoint was the pathological complete response assessed by two independent pathologists and was defined as no residual viable tumours at both the primary tumour site and all the lymph nodes. The secondary endpoints included adverse events and overall survival time. In total, 85.4% of patients experienced adverse events of any grade, and 4.2% reported Grade 3 adverse events; 45 patients underwent pathological evaluation, 14 (31.1%, 95% confidence interval, 18.2-46.6%) achieved pathological complete response, and the two-year survival rate was 88.3%. Imaging mass cytometry revealed that patients without pathological complete response presented immunosuppressive molecule expression, and expanded immunosuppressive fibroblast neighbourhoods. Here we show, serplulimab and chemotherapy are associated with modest antitumour activity and a tolerable safety profile in patients with locally advanced oesophageal squamous cell carcinoma. A phase 3 randomised trial featuring continued follow-up is essential for a formal evaluation. ClinicalTrials.gov identifier: NCT05659251.

> **中文摘要：**
> 在这项Ⅱ期临床试验中，诊断为局部进展期食管鳞状细胞癌的患者接受了三周期的新辅助治疗，方案包括赛普利利单抗、卡铂和白蛋白紫杉醇。主要终点为病理学完全缓解率，由两名独立病理学家评估，定义为原发肿瘤部位及所有淋巴结中均无存活肿瘤细胞。次要终点包括不良事件及总体生存时间。结果显示，85.4%的患者经历了任意级别的不良事件，4.2%的患者出现了3级不良事件；共45例患者接受病理学评估，其中14例（31.1%，95%置信区间18.2-46.6%）实现了病理学完全缓解，两年生存率为88.3%。成像质谱流式分析显示，未达到病理学完全缓解的患者中存在免疫抑制分子表达及扩大的免疫抑制性成纤维细胞邻域。研究结果表明，赛普利利单抗联合化疗在局部进展期食管鳞状细胞癌患者中具有适度的抗肿瘤活性及可耐受的安全性。需要进行持续随访的Ⅲ期随机对照试验以进行正式评估。ClinicalTrials.gov注册号：NCT05659251。

### 第二部分 AI 大师评价

本研究旨在评估赛普利利单抗联合化疗作为新辅助治疗在可切除食管鳞癌患者中的疗效与安全性。结果显示，该方案可实现约三成的病理完全缓解率，并维持较高的两年生存率，且总体耐受性良好。成像质谱流式分析揭示免疫微环境特征与疗效相关，为理解免疫治疗反应机制提供了线索。尽管为单臂Ⅱ期研究，样本量有限且缺乏对照组，但结果为后续Ⅲ期随机试验奠定了基础。

---

## 12. 溶酶体沿微管的力敏动态调控集体细胞迁移过程中领头细胞的出现

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/41423618)
**期刊：** Nature communications
**PMID：** 41423618
**DOI：** 10.1038/s41467-025-67645-0

### 第一部分 原文与翻译

**英文原标题：** Mechanosensitive dynamics of lysosomes along microtubules regulate leader cell emergence during collective cell migration.

> **英文摘要：**
> Collective cell migration during embryonic development, wound healing, and cancer metastasis requires the emergence of leader cells at the migration front. Despite their physiological relevance, the full mechanisms underlying the emergence of leader cells remain elusive. Here we report that leader cells display a peripheral accumulation of lysosomes in diverse model systems for wound healing, including cultured epithelial monolayer, mouse embryonic skin, and Drosophila embryos. This accumulation involves cellular contractile forces driving lysosomal transport along microtubules towards the leading edge. Indeed, we control leader cell emergence by manipulating lysosomal movement on microtubules. We further find that peripheral lysosomes associate with Rac1 molecules at the leading periphery, regulating local Rac1-activity, triggering actin polymerization and promoting lamellipodium formation. Taken together, we demonstrate that beyond their catabolic role, lysosomes act as an intracellular platform that links mechanical and biochemical signals to control the emergence of leader cells.

> **中文摘要：**
> 在胚胎发育、创伤愈合和癌症转移过程中，集体细胞迁移需要在迁移前沿出现领头细胞。尽管其生理意义重大，但主导领头细胞出现的完整机制仍不清楚。在本研究中，我们报道了在多种创伤愈合模型系统中（包括培养的上皮单层、鼠胚皮肤以及果蝇胚胎），领头细胞表现出溶酶体在细胞边缘的积聚。这种积聚过程涉及细胞收缩力驱动溶酶体沿微管向前缘运输。事实上，我们通过操控溶酶体在微管上的运动，实现了对领头细胞出现的控制。进一步研究发现，外围溶酶体与位于前沿的Rac1分子结合，从而调控局部Rac1活性，诱发肌动蛋白聚合并促进片状伪足的形成。综上所述，我们证明了溶酶体不仅具有分解代谢功能，还作为细胞内连接机械与生化信号的平台，从而调控领头细胞的出现。

### 第二部分 AI 大师评价

该研究从细胞力学与亚细胞器动态结合的角度揭示了溶酶体在集体迁移领头细胞形成中的关键作用。作者利用多种动物模型和实验操控手段，阐明溶酶体沿微管的力敏运输与前缘信号分子Rac1的空间调控关系。这一发现将溶酶体的作用从传统的降解代谢扩展至机械与信号整合的调控平台，具有显著创新性。其局限在于尚需进一步解析溶酶体力敏响应的分子机制及其在病理状态下的普适性。

---

## 13. 抗生素使用与乳腺癌生存的关系：一项在英国和威尔士开展的人群队列研究

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/41423616)
**期刊：** Nature communications
**PMID：** 41423616
**DOI：** 10.1038/s41467-025-67800-7

### 第一部分 原文与翻译

**英文原标题：** Antibiotic use and survival from breast cancer: A population-based cohort study in England and Wales.

> **英文摘要：**
> The role of the gut microbiota in carcinogenesis is increasingly being acknowledged. Recent studies in multiple breast cancer mouse models have found that antibiotics, by altering the gut microbiota, can accelerate tumour growth. In humans, a recent cohort study restricted to triple negative breast cancer showed that breast cancer patients using a greater number of antibiotics had markedly worse survival. These studies have raised concerns about repeated antibiotic use in breast cancer patients. In this Registered Report, we investigated whether breast cancer patients using oral antibiotics had increased breast cancer-specific mortality. In population-based cohorts (n = 44,452), we did not observe a statistically significant association between antibiotic prescriptions after diagnosis and breast cancer-specific mortality (adjusted HR = 1.07 95% CI 0.87, 1.33) apart from prescriptions of 12 or more antibiotics (adjusted HR = 1.62 95% CI 1.31, 2.01). This association was weaker after adjustment for infections (adjusted HR = 1.44 95% 1.14, 1.81), when restricted to antibiotics within five years (adjusted HR = 1.33 95% 0.95, 1.84), and was similar for deaths from other causes (adjusted HR = 1.69 95% 1.19, 2.41). Frequent antibiotic users had higher cancer-specific mortality but the attenuation of associations in sensitivity analyses, and similar findings for other causes of death, suggest this increase may reflect residual confounding. Protocol registration: The Stage 1 protocol for this Registered Report was accepted in principle on 7 November 2023. The protocol, as accepted by the journal, can be found at https://doi.org/10.6084/m9.figshare.24746721.v1.

> **中文摘要：**
> 肠道微生物群在肿瘤发生中的作用正日益受到认可。近期在多种乳腺癌小鼠模型中的研究发现，抗生素通过改变肠道微生物群，可加速肿瘤生长。在人类中，一项限于三阴性乳腺癌的队列研究显示，使用抗生素种类较多的乳腺癌患者，其生存情况明显较差。这些研究引发了对乳腺癌患者反复使用抗生素的担忧。在本注册报告中，我们探讨了乳腺癌患者使用口服抗生素是否会增加乳腺癌特异性死亡率。在基于人群的队列（n = 44,452）中，除开使用12种及以上抗生素（校正后风险比 = 1.62，95% 置信区间 1.31 至 2.01）外，我们未观察到诊断后抗生素处方与乳腺癌特异性死亡率之间存在统计学显著相关性（校正后风险比 = 1.07，95% 置信区间 0.87 至 1.33）。在校正感染因素后，该关联减弱（校正后风险比 = 1.44，95% 置信区间 1.14 至 1.81）；限于诊断后五年内的抗生素使用时，该关联进一步减弱（校正后风险比 = 1.33，95% 置信区间 0.95 至 1.84）；对于其他原因导致的死亡，其结果相似（校正后风险比 = 1.69，95% 置信区间 1.19 至 2.41）。频繁使用抗生素的患者具有较高的癌症特异性死亡率，但敏感性分析中关联的减弱，以及其他死亡原因中类似的发现，提示这种增加可能反映了残余混杂因素的影响。方案注册：本注册报告的第一阶段研究方案于2023年11月7日原则性通过。该方案可在 https://doi.org/10.6084/m9.figshare.24746721.v1 查阅。

### 第二部分 AI 大师评价

本研究基于英国和威尔士的大规模人群队列，探讨了乳腺癌患者使用抗生素与乳腺癌特异性死亡风险之间的关系。研究采用注册报告形式，确保研究设计的透明性和可重复性。主要结果显示，整体上抗生素处方与死亡风险无显著关联，但使用次数较多的患者可能存在风险上升；调整感染因素后该关联减弱。该研究在流行病学设计与敏感性分析方面具有严谨性，但仍可能受残余混杂影响，提示抗生素使用与癌症预后的关系需要进一步机制研究。

---

## 14. 异常的 KIF26B 表达通过驱动 NSUN2 核定位促进膀胱癌进展

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/41423602)
**期刊：** Journal of hematology & oncology
**PMID：** 41423602
**DOI：** 10.1186/s13045-025-01749-4

### 第一部分 原文与翻译

**英文原标题：** Aberrant KIF26B expression promotes bladder cancer progression through driving NSUN2 nuclear localization.

> **英文摘要：**
> Abnormal expression of kinesins has been observed in several types of cancer. The present study provided the first evidence that KIF26B could induce RNA mC modification in bladder cancer (BCa). Detailly, KIF26B interacted with NSUN2 and recruited ubiquitinase STUB1 to promote K63-linked ubiquitination of NSUN2 at K511 site. K63-linked ubiquitination enabled NSUN2 to bind to KPNA1 and translocate into nucleus where it drove RNA mC modification. Furthermore, KIF26B induced liquid-liquid phase separation (LLPS) of YBX1 and upregulated IL-6 expression through NSUN2/mC/YBX1 axis. Secreted IL-6 then activated STAT3 signaling to promote transcription of kif26b through direct binding between STAT3 and kif26b promoter. IL-6 also recruited DLAT to acetylate NSUN2 at K229 site and increased association affinity between NSUN2 and KIF26B. Together, these established a KIF26B/NSUN2/mC/IL-6 positive feedback loop, suggesting that targeting KIF26B may be a promising therapeutic strategy for BCa.

> **中文摘要：**
> 有丝分裂蛋白异常表达已在多种癌症类型中被观察到。本研究首次提供证据表明，KIF26B 可在膀胱癌（BCa）中诱导 RNA mC 修饰。具体而言，KIF26B 与 NSUN2 相互作用，并募集泛素化酶 STUB1 促进 NSUN2 在 K511 位点发生 K63 连接型泛素化。该 K63 连接型泛素化使 NSUN2 能够结合 KPNA1 并转位入核，在核内驱动 RNA mC 修饰。此外，KIF26B 还诱导 YBX1 的液-液相分离（LLPS），并通过 NSUN2/mC/YBX1 轴上调 IL-6 的表达。分泌的 IL-6 进一步激活 STAT3 信号通路，并通过 STAT3 与 kif26b 启动子的直接结合促进 kif26b 的转录。IL-6 还募集 DLAT 在 K229 位点对 NSUN2 进行乙酰化，从而增强 NSUN2 与 KIF26B 的结合亲和力。综上，这些结果构建了 KIF26B/NSUN2/mC/IL-6 正反馈环路，提示靶向 KIF26B 可能成为治疗膀胱癌的潜在策略。

### 第二部分 AI 大师评价

本研究揭示了 KIF26B 在膀胱癌进展中的关键分子机制，发现其通过调控 NSUN2 的核内定位及 RNA mC 修饰促进肿瘤发生。作者进一步阐明了 KIF26B 与 NSUN2、IL-6、STAT3 之间形成正反馈环路的分子基础，揭示了表观转录后修饰与细胞信号网络之间的交叉调控。该研究不仅在机制上具有创新性，也为靶向 KIF26B 的治疗策略提供了理论支持；然而，其临床可行性尚需进一步验证。

---

## 15. 呋喹替尼联合信迪利单抗用于错配修复功能正常的晚期子宫内膜癌患者的多中心、单臂 Ib/II 期试验

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/41423492)
**期刊：** Nature communications
**PMID：** 41423492
**DOI：** 10.1038/s41467-025-67375-3

### 第一部分 原文与翻译

**英文原标题：** Fruquintinib plus sintilimab in patients with advanced endometrial cancer with mismatch-repair proficient status: a multicenter, single-arm, phase Ib/II trial.

> **英文摘要：**
> This report presents the primary analysis of the endometrial cancer (EMC) cohort of FRUSICA-1 (ClinicalTrials.gov identifier, NCT03903705), a multicenter, single-arm, phase Ib/II study evaluating fruquintinib plus sintilimab. The cohort included Chinese patients with inoperable or advanced mismatch-repair proficient (pMMR) EMC who had progressed on or could not tolerate up to two prior platinum-based therapies, and comprised exploratory and pivotal phases. Patients received fruquintinib (5 mg orally once daily on a 2 weeks on/1 week off schedule) plus sintilimab (200 mg intravenously once every 3 weeks). The primary endpoint was objective response rate (ORR) assessed by an independent review committee (IRC). Secondary endpoints included ORR as assessed by the investigator, disease control rate, time to response, duration of response, progression-free survival (PFS) and tumor shrinkage as assessed by both the IRC and investigator, overall survival, and safety. By May 15, 2024, 98 patients with pMMR EMC were enrolled and treated. IRC-assessed ORR was 32.7% (95% confidence interval [CI] 23.5-42.9) for the total pMMR population (n = 98) and 31.6% (95% CI 21.4-43.3) for the pivotal population (n = 76). Median PFS was 8.6 months (95% CI 5.5-16.6) for the total population and 7.1 months (95% CI 5.4-16.6) for the pivotal population. The most common grade ≥3 treatment-related adverse event was hypertension (17.3%). In conclusion, fruquintinib plus sintilimab showed promising efficacy and tolerable safety in previously treated, advanced pMMR EMC.

> **中文摘要：**
> 本报告呈现了 FRUSICA-1 研究（ClinicalTrials.gov 注册号：NCT03903705）中子宫内膜癌（EMC）队列的主要分析结果。FRUSICA-1 为一项多中心、单臂的 Ib/II 期研究，旨在评估呋喹替尼联合信迪利单抗的疗效与安全性。研究队列纳入了中国境内无法手术或晚期、且为错配修复功能正常（pMMR）的 EMC 患者，这些患者在既往最多两线含铂方案治疗后出现疾病进展或无法耐受，研究包括探索性和关键性阶段。患者接受呋喹替尼治疗（5 mg，每日口服一次，按“服药两周、停一周”周期）联合信迪利单抗（200 mg，每 3 周静脉输注一次）。主要终点为由独立评审委员会（IRC）评估的客观缓解率（ORR）。次要终点包括研究者评估的 ORR、疾病控制率、缓解所需时间、缓解持续时间、无进展生存期（PFS）及肿瘤缩小率（由 IRC 和研究者均评估）、总生存期及安全性。截至 2024 年 5 月 15 日，共有 98 例 pMMR EMC 患者入组并接受治疗。IRC 评估的总体 pMMR 人群（n=98）ORR 为 32.7%（95% 置信区间 [CI]：23.5–42.9），关键人群（n=76）ORR 为 31.6%（95% CI：21.4–43.3）。总体人群的中位 PFS 为 8.6 个月（95% CI：5.5–16.6），关键人群为 7.1 个月（95% CI：5.4–16.6）。最常见的 ≥3 级治疗相关不良事件为高血压（17.3%）。综上所述，呋喹替尼联合信迪利单抗在既往接受过治疗的晚期 pMMR EMC 患者中显示出令人鼓舞的疗效及可接受的安全性。

### 第二部分 AI 大师评价

本研究为一项多中心、单臂 Ib/II 期临床试验，探索抗血管生成药物呋喹替尼联合抗 PD-1 抗体信迪利单抗在错配修复功能正常的晚期子宫内膜癌中的疗效与安全性。结果显示，该联合方案在既往治疗失败患者中取得了较高的客观缓解率及较长的中位无进展生存期，安全性特征可控。研究创新性在于针对传统免疫治疗反应率较低的 pMMR 人群提供了新的治疗思路。局限性包括单臂设计及研究对象局限于中国人群，需要后续随机对照研究进一步验证。

---

## 16. 滑膜肉瘤通过GBAF激活多梳靶基因并丧失CBAF增强子来重编程转录。

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/41423472)
**期刊：** Nature communications
**PMID：** 41423472
**DOI：** 10.1038/s41467-025-67841-y

### 第一部分 原文与翻译

**英文原标题：** Synovial sarcoma reprograms transcription by GBAF activation of polycomb targets and loss of CBAF enhancers.

> **英文摘要：**
> Synovial sarcoma is a cancer driven by a fusion oncoprotein, SS18::SSX, that links SS18, a subunit of BAF-family chromatin remodeling complexes, to the carboxy terminus of SSX, which avidly binds nucleosomes with the histone post-translational modification H2AK119ub. Here, we show in mice that SS18::SSX expression redistributes non-canonical GBAF complexes broadly to promoters and distal enhancers marked by H2AK119ub, which causes developmental loci to lose H3K27me3 and become transcriptionally active. Canonical BAF containing SS18::SSX abandons its typical binding sites, is largely absent from H2AK119ub-marked sites, and instead distributes narrowly to transcription start sites with PBAF. Disruption of Arid1a or Arid1b (both CBAF-specific) retains synovial sarcoma character, while Smarcb1 (PBAF- and CBAF-specific) or Pbrm1 (PBAF-specific) disruption does not, although all accelerate SS18::SSX-driven tumorigenesis in mice. Thus, the synovial sarcomagenesis mechanism involves SS18::SSX reprogramming transcription positively through GBAF redistribution to activate polycomb-targeted developmental genes, and negatively by loss of normal CBAF localization and function.

> **中文摘要：**
> 滑膜肉瘤是一种由融合癌蛋白 SS18::SSX 驱动的癌症。该蛋白将作为 BAF 家族染色质重塑复合物亚基的 SS18 与能够高亲和力结合具有组蛋白翻译后修饰 H2AK119ub 的核小体的 SSX 的羧基末端连接起来。在本研究中，我们在小鼠中发现，SS18::SSX 的表达使非典型 GBAF 复合物大范围重新分布到由 H2AK119ub 标记的启动子和远端增强子上，从而导致发育相关基因位点失去 H3K27me3 并转变为转录活跃状态。含有 SS18::SSX 的典型 BAF 放弃了其典型的结合位点，在 H2AK119ub 标记位点上基本缺失，而是与 PBAF 一起狭窄地分布于转录起始位点。破坏 Arid1a 或 Arid1b（均为 CBAF 特异性）后，滑膜肉瘤的特征得以保留，而破坏 Smarcb1（PBAF 和 CBAF 特异性）或 Pbrm1（PBAF 特异性）则不会保留此特征，尽管这些破坏在小鼠中都会加速 SS18::SSX 驱动的肿瘤发生。因此，滑膜肉瘤的发生机制包括两方面：其一，SS18::SSX 通过重新分配 GBAF 激活多梳靶向的发育基因，从而正向重编程转录；其二，由于正常 CBAF 的定位与功能丧失而导致负向调控。

### 第二部分 AI 大师评价

该研究揭示了滑膜肉瘤的转录重编程机制，阐明了融合癌蛋白 SS18::SSX 通过重定向 GBAF 复合物激活多梳靶基因、同时破坏 CBAF 功能的双重作用路径。研究团队利用小鼠模型系统地剖析了不同 BAF 亚型复合物成员（包括 Arid1a、Arid1b、Smarcb1、Pbrm1）在滑膜肉瘤形成中的功能差异。结果表明，GBAF 的异常重新分布是滑膜肉瘤转录激活与发育基因去抑制的关键驱动力。该工作在机制层面上深化了对染色质重塑复合体异质性及其在肿瘤发生中作用的理解，但仍需进一步探索这些机制在人类病变中的普适性。

---

## 17. 孕激素受体抑制通过促进G6PD表达增强腔型乳腺癌的恶性程度

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/41423458)
**期刊：** Cell death & disease
**PMID：** 41423458
**DOI：** 10.1038/s41419-025-08365-7

### 第一部分 原文与翻译

**英文原标题：** PR inhibition stimulates G6PD expression to enhance malignancy in luminal breast cancer.

> **英文摘要：**
> Luminal breast cancer is the most prevalent and prognostic subtype of breast cancer. However, it has been reported that luminal breast cancer patients with lower progesterone receptor (PR) expression are associated with poor survival outcomes. Nevertheless, there is insufficient evidence linking PR expression to an aggressiveness of luminal breast cancer. Based on our previous studies showing an inverse correlation between PR and standardized uptake value (SUV) on [18 F] fluorodeoxyglucose positron emission tomography (FDG-PET), we aimed to identify a potential link between PR expression and glucose metabolism, particularly the pentose phosphate pathway (PPP). To investigate it, we performed a single cell RNA sequencing (scRNA-seq) analysis using published dataset. Interestingly, the analysis revealed that specific epithelial cells with both increased proliferation activity and decreased PR expression, which increased activity of the PPP and glucose-6-phosphate dehydrogenase (G6PD) expression. To verify these findings, we silenced PR expression in the luminal breast cancer cell lines, MCF7 and T47D, which led to accelerated proliferation and PPP activity with G6PD expression. We hypothesized that PR knockdown (KD) increases breast cancer aggressiveness by boosting glucose utilization with PPP activity. Importantly, treatment with G6PD inhibitor (G6PDi), a G6PDi reduced aggressiveness of PR KD cancer cells. These findings suggest that targeting G6PD could be a promising therapeutic strategy to suppress the aggressiveness of luminal breast cancer, using low PR expression as a biomarker.

> **中文摘要：**
> 腔型乳腺癌是乳腺癌中最常见且具有预后意义的亚型。然而，有报告指出，孕激素受体（PR）表达较低的腔型乳腺癌患者与较差的生存结局相关。然而，目前缺乏将PR表达与腔型乳腺癌侵袭性直接关联的充分证据。基于我们先前的研究显示，在[18F]氟脱氧葡萄糖正电子发射断层扫描（FDG-PET）中，PR与标准摄取值（SUV）呈负相关，我们旨在确定PR表达与葡萄糖代谢之间的潜在联系，尤其是磷酸戊糖途径（PPP）。为探究这一点，我们利用已发表的数据集进行了单细胞RNA测序（scRNA-seq）分析。有趣的是，分析结果显示，某些上皮细胞同时表现为增殖活性增强及PR表达下降，这类细胞表现出更高的PPP活性及葡萄糖-6-磷酸脱氢酶（G6PD）表达。为验证这些发现，我们在腔型乳腺癌细胞系MCF7与T47D中沉默PR表达，结果导致细胞增殖和PPP活性加速，并伴随G6PD表达上调。我们推测，PR敲低（KD）可能通过增强PPP介导的葡萄糖利用，从而提升乳腺癌的侵袭性。更重要的是，使用G6PD抑制剂（G6PDi）处理能够降低PR敲低癌细胞的侵袭性。这些发现表明，以低PR表达为生物标志物、靶向G6PD可能成为抑制腔型乳腺癌侵袭性的有前景治疗策略。

### 第二部分 AI 大师评价

该研究聚焦于PR表达下降与腔型乳腺癌侵袭性增强之间的机制联系，通过单细胞转录组学和功能实验揭示了PR抑制可上调G6PD并激活磷酸戊糖途径，从而促进葡萄糖代谢和细胞增殖。进一步，研究验证G6PD抑制剂可逆转此效应，提示G6PD是潜在治疗靶点。该研究的创新性在于将内分泌受体信号与代谢重编程联系起来，拓展了腔型乳腺癌的代谢机制认识。但其局限在于临床样本验证尚有限，未来需在更大队列中进一步确认临床可行性。

---

## 18. FDX1深度突变扫描揭示脂酰化与铜死亡的关键结构决定因素

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/41423452)
**期刊：** Nature communications
**PMID：** 41423452
**DOI：** 10.1038/s41467-025-67869-0

### 第一部分 原文与翻译

**英文原标题：** Deep Mutational Scanning of FDX1 Identifies Key Structural Determinants of Lipoylation and Cuproptosis.

> **英文摘要：**
> Cuproptosis is a recently described form of regulated cell death triggered by ionophore-induced copper (Cu) overload in mitochondria. It is critically dependent on ferredoxin 1 (FDX1), a mitochondrial iron-sulfur cluster containing protein that acts as an electron shuttle. FDX1 reduces ionophore-bound Cu(II) to Cu(I), thereby triggering its release, and promotes mitochondrial protein lipoylation, which is directly targeted by the released copper to drive cell death. Despite the pivotal role of FDX1 in cuproptosis, the structural determinants underlying its distinct functions remain unclear. To address this, we performed deep mutational scanning on FDX1 and find that two conserved solvent-exposed residues, D136 and D139, on alpha helix 3 are essential for both cuproptosis and lipoylation. Charge-reversal mutations at these positions abolish FDX1's ability to induce cuproptosis and support lipoylation in cells, despite retaining full enzymatic activity in vitro. Guided by structural and genomic analyses, we further identify dihydrolipoamide dehydrogenase (DLD), the E3 subunit of lipoylated complexes as an alternative FDX1 reductase both in cells and in vitro. Together, these findings establish the acidic alpha helix 3 of FDX1 as a critical interface for its upstream regulation and suggest that FDX1's roles in cuproptosis and in lipoylation are both structurally and functionally linked.

> **中文摘要：**
> 铜死亡（Cuproptosis）是一种新近被描述的受调控的细胞死亡形式，由离子载体诱导的线粒体内铜（Cu）过载触发。它关键依赖于铁氧还蛋白1（FDX1），一种含铁硫簇的线粒体蛋白，发挥电子穿梭作用。FDX1将与离子载体结合的Cu(II)还原为Cu(I)，从而诱导铜的释放，并促进线粒体蛋白的脂酰化，而释放的铜可直接作用于这些脂酰化蛋白以驱动细胞死亡。尽管FDX1在铜死亡中具有关键作用，但其不同功能所依赖的结构决定因素仍不明确。为了解决这一问题，我们对FDX1进行了深度突变扫描，发现位于α螺旋3上的两个保守的溶剂暴露残基D136和D139对铜死亡和脂酰化均至关重要。在这些位点的电荷反转突变会削弱FDX1诱导铜死亡和促进细胞内脂酰化的能力，尽管其在体外仍保持完整的酶活性。通过结构和基因组学分析，我们进一步鉴定出二氢硫辛酰胺脱氢酶（DLD），即脂酰化复合物的E3亚基，是细胞内外FDX1的另一种替代还原酶。总体而言，这些发现确立了FDX1酸性α螺旋3作为其上游调控关键界面的地位，并表明FDX1在铜死亡与脂酰化中的作用在结构与功能上密切相关。

### 第二部分 AI 大师评价

本研究通过对FDX1进行深度突变扫描，揭示其α螺旋3上的D136和D139残基是决定铜死亡与脂酰化功能的关键结构要素。作者发现，这些残基的电荷反转突变会破坏FDX1的生理功能，而不影响其酶活性，提示FDX1的结构界面对功能调控具有核心作用。同时，研究识别出DLD作为细胞内外的替代FDX1还原酶，进一步拓展了铜死亡分子网络的认识。该研究在机制阐明上具有创新性，但其生理后果及在疾病模型中的验证仍需进一步探索。

---

## 19. YTHDF1通过抑制NOTCH1诱导的干性调控结直肠癌的化疗反应。

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/41423446)
**期刊：** Signal transduction and targeted therapy
**PMID：** 41423446
**DOI：** 10.1038/s41392-025-02507-1

### 第一部分 原文与翻译

**英文原标题：** YTHDF1 targets the chemotherapy response by suppressing NOTCH1-induced stemness in colorectal cancer.

> **英文摘要：**
> N-methyladenosine (mA) modification of mRNAs is a predominant epigenetic regulatory mechanism in tumor initiation and progression. Cancer stem cells (CSCs) are the key drivers of colorectal cancer (CRC) initiation and chemotherapy resistance. Here, we found that the mA reader YT521-B homologous domain family, member 1 (YTHDF1), promotes CRC stemness, tumorigenesis, and chemotherapy resistance. YTHDF1 protein expression was positively correlated with CD133 and LGR5 expression in human CRC tissues (N = 184, P < 0.001 for both markers). YTHDF1 promoted mA-dependent self-renewal in CSCs and patient-derived organoids and increased the tumor-initiating potential in vivo. Lgr5-specific Ythdf1-KI mice presented accelerated Apc (P < 0.05) and AOM/DSS (P < 0.05)-induced colorectal tumorigenesis, whereas Lgr5-specific Ythdf1 knockout in Apc mice inhibited tumorigenesis (P < 0.01). Integrative multiomic profiling revealed NOTCH1 as a downstream target. YTHDF1 binds mA-modified NOTCH1, promoting its translation and enhancing NOTCH signaling. NOTCH1 knockdown or blockade by the γ-secretase inhibitor DAPT abolished YTHDF1-mediated tumorigenesis in Ythdf1 knock-in mice (P < 0.01). YTHDF1 promoted resistance to oxaliplatin and 5-fluorouracil in CSCs by inhibiting apoptosis and DNA damage. AOM/DSS-treated Ythdf1 knock-in mice presented increased resistance to oxaliplatin (P < 0.001) and 5-fluorouracil (P < 0.05). Translationally, in vivo targeting of YTHDF1 via VNP-encapsulated siYTHDF1 or salvianolic acid C inhibited tumor growth (P < 0.05 for both treatments) and increased treatment efficacy when VNP was combined with oxaliplatin (P < 0.05, SAC: P < 0.01) or 5-fluorouracil (P < 0.05 for both treatments). In conclusion, YTHDF1 promotes stemness and chemoresistance in CRC via NOTCH1 activation. Targeting YTHDF1 is a promising strategy to improve the outcome of chemotherapy in CRC.

> **中文摘要：**
> mRNA的N-甲基腺苷（mA）修饰是肿瘤发生与进展中的主要表观遗传调控机制。癌症干细胞（CSCs）是结直肠癌（CRC）发生及化疗耐药的关键驱动力。本研究发现，mA识别蛋白YT521-B同源结构域家族成员1（YTHDF1）可促进CRC的干性、肿瘤形成及化疗耐药。在人类CRC组织中（N=184），YTHDF1蛋白的表达与CD133和LGR5的表达呈显著正相关（两者P均<0.001）。YTHDF1在CSC及患者来源的类器官中促进依赖mA修饰的自我更新，并在体内增强肿瘤起始潜能。Lgr5特异性Ythdf1-KI小鼠中，Apc（P<0.05）和AOM/DSS（P<0.05）诱导的结直肠肿瘤形成加快，而Apc小鼠中Lgr5特异性Ythdf1敲除则抑制了肿瘤发生（P<0.01）。综合多组学分析揭示NOTCH1为下游靶点。YTHDF1结合mA修饰的NOTCH1，促进其翻译并增强NOTCH信号通路。敲低NOTCH1或以γ-分泌酶抑制剂DAPT阻断该通路，可消除Ythdf1敲入小鼠中YTHDF1介导的肿瘤生成效应（P<0.01）。YTHDF1通过抑制细胞凋亡和DNA损伤，增强CSC对奥沙利铂和5-氟尿嘧啶的耐药性。AOM/DSS处理的Ythdf1敲入小鼠对奥沙利铂（P<0.001）和5-氟尿嘧啶（P<0.05）表现出更强的耐药性。在转化应用层面，通过VNP包封的siYTHDF1或丹参酸C靶向抑制YTHDF1可抑制肿瘤生长（两种处理均P<0.05），且当VNP分别与奥沙利铂（P<0.05，SAC：P<0.01）或5-氟尿嘧啶（两者均P<0.05）联合使用时，治疗效果进一步增强。综上，YTHDF1通过激活NOTCH1信号通路促进CRC干性与化疗耐药，靶向YTHDF1有望成为改善CRC化疗效果的潜在策略。

### 第二部分 AI 大师评价

本研究揭示了YTHDF1在结直肠癌中通过调控m6A修饰的NOTCH1翻译，增强肿瘤干性与化疗耐药的新机制。研究结合体内外功能实验及多组学分析，明确了YTHDF1在癌症干细胞维持和药物反应中的关键作用。在动物模型中，敲除或抑制YTHDF1可显著降低肿瘤生成与耐药性，提示其作为治疗靶点的潜在价值。创新之处在于将m6A表观转录调控与NOTCH信号轴直接联系，为CRC化疗敏感性调控提供了新的分子基础。局限性在于对YTHDF1上下游调控网络及其临床转化可行性仍需进一步验证。

---

## 20. 癌相关成纤维细胞通过 COL4A1 介导胃癌的免疫抑制：潜在的治疗靶点

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/41423274)
**期刊：** Journal for immunotherapy of cancer
**PMID：** 41423274
**DOI：** 10.1136/jitc-2025-013577

### 第一部分 原文与翻译

**英文原标题：** CAFs mediate immunosuppression in gastric cancer via COL4A1: potential therapeutic targets.

> **英文摘要：**
> BACKGROUND: The immunomodulatory roles of cancer-associated fibroblasts (CAFs) in gastric cancer have been increasingly recognized. This study aimed to identify specific CAF subpopulations and to elucidate the mechanisms underlying their immunosuppressive effects.
> 
> METHODS: We developed a single-cell RNA sequencing (scRNA-seq) protocol to enrich CAFs and matched normal fibroblasts (NFs) from stomach tissues. Bioinformatics analyses, along with in vitro and in vivo experiments, were performed to functionally validate a distinct CAF subset.
> 
> RESULTS: We profiled 8,322 high-quality fibroblasts from nine patient-matched tumor and adjacent normal tissue pairs. A unique CAF subset,  CAFs, was identified.  CAFs were significantly enriched in the tumor microenvironment and associated with poor survival and M2-like macrophage infiltration. Tumor cells promoted  CAFs expansion via JAG1-NOTCH3 and LGALS3-CD146 signaling. Mechanistically, NOTCH3 acted as a master regulator in  CAFs. Tumor cell-derived JAG1 engaged NOTCH3 on  CAFs, which triggered PI3K/AKT-mediated CD146 transcription and enhanced COL4A1 secretion. Functionally,  CAF-derived COL4A1 bound macrophage CD44/IL7R to drive macrophage M2-like polarization, thereby suppressing CD8 T-cell function. Therapeutic blockade of CD146 or COL4A1 in vivo impaired M2 polarization, reinvigorated CD8 T-cell activity, and restrained tumor growth.
> 
> CONCLUSIONS: Our findings underscore the pivotal role of  CAFs in shaping an immunosuppressive microenvironment and highlight  CAFs and COL4A1 as promising candidates for targeted therapy in gastric cancer.

> **中文摘要：**
> 背景：癌相关成纤维细胞（CAFs）在胃癌中的免疫调节作用日益受到关注。本研究旨在鉴定特定的 CAF 亚群，并阐明其免疫抑制效应的潜在机制。
> 
> 方法：我们建立了一种单细胞 RNA 测序（scRNA-seq）方案，用于从胃组织中富集 CAFs 及匹配的正常成纤维细胞（NFs）。结合生物信息学分析以及体外和体内实验，对一种功能上独特的 CAF 亚群进行了验证。
> 
> 结果：我们对来自九对患者匹配的肿瘤及邻近正常组织中的 8,322 个高质量成纤维细胞进行了谱系分析。发现了一种独特的 CAF 亚群，该亚群在肿瘤微环境中显著富集，并与生存预后不良及 M2 型样巨噬细胞浸润相关。肿瘤细胞通过 JAG1-NOTCH3 和 LGALS3-CD146 信号通路促进该 CAF 亚群的扩增。在机制上，NOTCH3 在该亚群中作为关键调控因子。肿瘤细胞来源的 JAG1 与 CAFs 上的 NOTCH3 结合，触发 PI3K/AKT 介导的 CD146 转录并增强 COL4A1 的分泌。在功能上，CAF 来源的 COL4A1 与巨噬细胞的 CD44/IL7R 结合，驱动其向 M2 型极化，从而抑制 CD8 T 细胞功能。体内阻断 CD146 或 COL4A1 的治疗可削弱 M2 极化，恢复 CD8 T 细胞活性，并抑制肿瘤生长。
> 
> 结论：我们的研究强调了该 CAF 亚群在塑造免疫抑制性微环境中的关键作用，并指出该 CAF 亚群及 COL4A1 是胃癌靶向治疗的有前景候选靶点。

### 第二部分 AI 大师评价

本研究通过单细胞转录组学揭示了胃癌中一种独特的癌相关成纤维细胞亚群，其通过 COL4A1 介导的信号通路诱导巨噬细胞 M2 型极化并抑制 CD8 T 细胞功能。研究采用了系统的生物信息学及实验验证，明确了 JAG1-NOTCH3-CD146-COL4A1 轴的关键调控作用。其创新性体现在明确了 CAFs 的分子机制并提出可行的治疗干预靶点。该研究为免疫微环境调控与胃癌靶向治疗提供了新的方向，但仍需进一步临床验证以评估其转化潜力。

---

## 21. 结合C反应蛋白激增与早期MRI动态以增强免疫治疗反应预测

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/41423273)
**期刊：** Journal for immunotherapy of cancer
**PMID：** 41423273
**DOI：** 10.1136/jitc-2025-012143

### 第一部分 原文与翻译

**英文原标题：** Integrating C-reactive protein flare and early MRI dynamics for enhanced prediction of immunotherapy response.

> **英文摘要：**
> BACKGROUND: The C-reactive protein (CRP) flare response, an indicator of early immune activation, has emerged as a promising and cost-effective biomarker for predicting response to immune checkpoint inhibitors (ICIs) across various tumor types. This study evaluates the utility of CRP dynamics as a tumor-agnostic biomarker and integrates systemic inflammatory markers with advanced multiparametric MRI metrics to uncover the biological mechanisms underlying the CRP flare phenomenon and its relationship with treatment response.
> 
> METHODS: Patients were stratified into three groups based on CRP kinetics: (1) flare-responders, characterized by an initial doubling of baseline CRP followed by a decrease below baseline; (2) CRP responders, defined as patients with no flare increase but a CRP reduction of at least 30% below baseline and (3) CRP non-responders. Multiparametric MRI was performed at baseline, early (1-3 weeks), and intermediate (6-8 weeks) time points to assess tumor size and microstructural features, including cell density and vascularization. Clinical benefit and survival outcomes, including progression-free survival (PFS) and overall survival (OS), were analyzed using Kaplan-Meier curves and log-rank tests. Cox regression analyses were performed to identify independent predictors of clinical outcomes, while intergroup differences in MRI metrics were assessed using Wilcoxon rank-sum and Kruskal-Wallis tests.
> 
> RESULTS: Among the 121 evaluable patients with solid tumors enrolled in the PREDICT trial, CRP flare-responders demonstrated significantly longer PFS (5.6 months) and OS (12.1 months) compared with responders (PFS: 3.4 months, OS: 8.0 months) and non-responders (PFS: 3.2 months, OS: 6.7 months; p=0.01 and p<0.01, respectively). Additionally, clinical benefit was achieved in 50% of flare-responders, compared with 13% of responders (p=0.05) and 23% of non-responders (p<0.01). Tumor growth was interrupted early after treatment initiation in CRP flare-responders, whereas non-responders exhibited marked increases in tumor size. In the pilot subset of 33 patients with MRI data, diffusion MRI revealed stable or increased apparent diffusion coefficient values in CRP flare-responders, indicative of reduced tumor cellularity just after 1-3 weeks of treatment.
> 
> CONCLUSIONS: This study highlights the potential of combining early CRP dynamics with non-invasive imaging metrics to identify ICI responders as early as 2 weeks after treatment initiation. By integrating systemic inflammatory biomarkers with MRI-derived insights into tumor size and microstructural changes, these findings optimize therapeutic strategies and advance understanding of immunotherapy-driven tumor dynamics.

> **中文摘要：**
> 背景：C反应蛋白（CRP）的激增反应作为早期免疫激活的指标，已成为预测多种肿瘤类型中免疫检查点抑制剂（ICI）治疗反应的一个有前景且具成本效益的生物标志物。本研究评估了CRP动态作为肿瘤无关型生物标志物的实用性，并将系统性炎症标志物与先进的多参数MRI指标相结合，以揭示CRP激增现象背后的生物学机制及其与治疗反应的关系。
> 
> 方法：根据CRP动力学将患者分为三组：（1）激增反应者，其特征为CRP在基线的基础上先上升一倍，随后下降至基线以下；（2）CRP反应者，定义为CRP无激增上升但较基线下降至少30%的患者；（3）CRP无反应者。在基线、早期（1–3周）及中期（6–8周）进行多参数MRI，以评估肿瘤大小及微观结构特征，包括细胞密度和血管化情况。采用Kaplan-Meier曲线及log-rank检验分析临床获益和生存结局（包括无进展生存期PFS及总生存期OS），并通过Cox回归分析确定临床结局的独立预测因素；组间MRI指标差异采用Wilcoxon秩和检验及Kruskal-Wallis检验评估。
> 
> 结果：在PREDICT试验中纳入的121例可评估的实体瘤患者中，CRP激增反应者的PFS（5.6个月）和OS（12.1个月）均显著长于反应者（PFS：3.4个月，OS：8.0个月）和无反应者（PFS：3.2个月，OS：6.7个月；p=0.01和p<0.01）。此外，50%的激增反应者获得了临床获益，而反应者和无反应者分别为13%（p=0.05）和23%（p<0.01）。在治疗开始后，CRP激增反应者的肿瘤生长被早期抑制，而无反应者的肿瘤体积显著增加。在包含MRI数据的33例患者的试点子集中，弥散MRI显示CRP激增反应者在治疗1–3周后表观弥散系数（ADC）值稳定或升高，提示肿瘤细胞密度降低。
> 
> 结论：本研究突出显示，将早期CRP动态与无创影像学指标结合，可在治疗开始后2周内识别ICI反应者。通过整合系统性炎症生物标志物与MRI反映的肿瘤大小及微结构变化，这些发现有助于优化治疗策略，并加深对免疫治疗驱动肿瘤动态的理解。

### 第二部分 AI 大师评价

该研究创新性地将C反应蛋白的动态变化与早期多参数MRI影像特征相结合，用于预测免疫治疗的反应情况。其方法通过分层CRP动力学并结合影像学指标，揭示了免疫激活与肿瘤微环境变化的早期关系。结果表明CRP激增者在无进展生存期与总生存期方面均有显著获益。研究的亮点在于其跨肿瘤类型的通用性及早期预测价值，但样本量相对有限，MRI子集分析仍需更大规模验证。

---

## 22. 结直肠癌中 的临床与分子特征研究：基于CALGB（联盟）/SWOG 80405试验及真实世界数据的分析

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/41423272)
**期刊：** Journal for immunotherapy of cancer
**PMID：** 41423272
**DOI：** 10.1136/jitc-2025-013186

### 第一部分 原文与翻译

**英文原标题：** Clinical and molecular characterization of  in colorectal cancer, CALGB (Alliance)/SWOG 80405 and real-world data.

> **英文摘要：**
> BACKGROUND: dysregulation is associated with both intrinsic resistance in tumor cells and reprogramming of the immune microenvironment. However, it is still unclear which patients would benefit from AXL-targeting therapies. We conducted a clinical and molecular characterization of  in colorectal cancer (CRC).
> 
> METHODS: This study integrated real-world molecular profiling (Caris cohort; n=24,257) and randomized clinical trial data (phase III Cancer and Leukemia Group B/Southwest Oncology Group (CALGB/SWOG) 80405; n=433) to assess  messenger RNA expression in patients with CRC. Tumor samples underwent RNA sequencing and analysis of the immune microenvironment.  expression was categorized into tertiles. We assessed associations between molecular features, immune biomarkers, and clinical outcomes, including overall survival (OS) and progression-free survival (PFS), using Kaplan-Meier and Cox proportional hazards models while adjusting for relevant covariates.
> 
> RESULTS: Elevated  expression correlated with increased programmed death-ligand 1 immunohistochemistry positivity (6.2% vs 2.5%, q<0.0001), immune checkpoint-related gene expression, and infiltration of immunosuppressive cell populations (T-regulatory cells, M2 macrophages, monocytes, and B cells). Pathway analyses demonstrated links between high  expression and epithelial-mesenchymal transition, inflammatory signaling, interferon-gamma response, and tumor necrosis factor alpha signaling. In the Caris cohort, high  predicted worse OS in patients treated with fluorouracil, leucovorin, and oxaliplatin/fluorouracil, leucovorin, and irinotecan (38.0 vs 34.7 months, p=0.027; HR 1.07), bevacizumab (36.8 vs 32.6 months, p=0.013; HR 1.21), and anti-epidermal growth factor receptor therapy (28.4 vs 22.2 months, p=0.005; HR 1.21), but profoundly improved OS in  mutant patients treated with immunotherapy (11.6 vs 23.4 months, p=0.012; HR 0.65). CALGB/SWOG 80405 findings confirmed shorter PFS (9.2 vs 12.9 months, p=0.001; HR 1.56) and OS (24.2 vs 34.7 months, p<0.001; HR 1.68) with high  expression across treatment arms.
> 
> CONCLUSIONS: Elevated  expression in CRC correlated with an immunosuppressive microenvironment and worse outcomes across standard treatments. However, it identifies a distinct subgroup of -mutant patients who significantly benefit from immunotherapy, supporting  as a context-specific biomarker and therapeutic target.

> **中文摘要：**
> 背景：的失调与肿瘤细胞的内在耐药性以及免疫微环境的重编程均有关。然而，目前仍不清楚哪些患者能从针对AXL的治疗中获益。我们对结直肠癌（CRC）中的 进行了临床和分子特征分析。
> 
> 方法：本研究整合了真实世界的分子特征数据（Caris队列；n=24,257）和随机临床试验数据（第三阶段癌症与白血病研究组/美国西南肿瘤组（CALGB/SWOG）80405；n=433），以评估CRC患者的 信使RNA表达。肿瘤样本接受RNA测序和免疫微环境分析，并将 的表达分为三分位组。我们采用Kaplan-Meier和Cox比例风险模型，调整相关协变量后分析分子特征、免疫生物标志物与临床结局（包括总生存期OS和无进展生存期PFS）之间的关系。
> 
> 结果： 的高表达与程序性死亡配体1免疫组化阳性率升高（6.2% vs 2.5%，q<0.0001）、免疫检查点相关基因表达增加及免疫抑制性细胞群（调节性T细胞、M2型巨噬细胞、单核细胞及B细胞）浸润增强相关。通路分析显示，高 表达与上皮-间质转化、炎症信号、干扰素γ反应及肿瘤坏死因子α信号有关。在Caris队列中，高 表达预测接受氟尿嘧啶、亚叶酸钙及奥沙利铂/氟尿嘧啶、亚叶酸钙及伊立替康治疗患者的总生存期较差（38.0 vs 34.7个月，p=0.027；HR 1.07），在使用贝伐珠单抗（36.8 vs 32.6个月，p=0.013；HR 1.21）及抗表皮生长因子受体治疗（28.4 vs 22.2个月，p=0.005；HR 1.21）的患者中亦如此，但在 接受免疫治疗的突变患者中则显著改善OS（11.6 vs 23.4个月，p=0.012；HR 0.65）。CALGB/SWOG 80405试验结果亦证实，在所有治疗方案中，高 表达与更短的PFS（9.2 vs 12.9个月，p=0.001；HR 1.56）及OS（24.2 vs 34.7个月，p<0.001；HR 1.68）相关。
> 
> 结论：结直肠癌中 的高表达与免疫抑制微环境及差的标准治疗结局相关。然而，它能识别出一类对免疫治疗显著获益的突变患者亚群，提示 可作为情境特异性生物标志物及潜在治疗靶点。

### 第二部分 AI 大师评价

本研究整合大型真实世界与随机临床试验数据，系统分析结直肠癌中 的表达模式及临床意义。结果显示，高 表达与免疫抑制环境及较差预后密切相关，但在突变亚群中显著改善免疫治疗反应，揭示其潜在的生物标志物价值。研究创新性地展示了分子特征与治疗反应之间的交互作用，具有重要转化意义。然而，结论仍需在更多前瞻性人群中进一步验证。

---

## 23. AMPK 激动剂可优化嵌合抗原受体 T 细胞的体内激活与抗白血病效能

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/41423271)
**期刊：** Journal for immunotherapy of cancer
**PMID：** 41423271
**DOI：** 10.1136/jitc-2024-010312

### 第一部分 原文与翻译

**英文原标题：** AMPK agonism optimizes the in vivo activation and antileukemic efficacy of chimeric antigen receptor T cells.

> **英文摘要：**
> BACKGROUND: Chimeric antigen receptor (CAR) T cells have achieved remarkable clinical success. However, up to 50% of patients with CAR T-cell treated leukemia relapse and long-term survivor data indicate that CAR T cell persistence is key to enforcing extended, relapse-free survival. Unfortunately, ex vivo expansion protocols often drive metabolic and functional exhaustion, reducing in vivo efficacy. Preclinical models have demonstrated that redirecting metabolism can improve in vivo T-cell function. Here, we hypothesized that exposure to an agonist targeting AMP-activated protein kinase (AMPK) would create CAR T cells capable of increased in vivo function and enhanced leukemia clearance.
> 
> METHODS: CAR T cells were generated from healthy human donor T cells via lentiviral transduction, followed by exposure to either Compound 991 or dimethyl sulfoxide (DMSO) for 96 hours. During and after agonist treatment, T cells were harvested for metabolic and functional assessments. To test in vivo efficacy, immunodeficient mice were injected with luciferase+NALM6 leukemia cells, and 1 week later with 991- versus DMSO-expanded CAR T cells. Leukemia burden and antileukemia efficacy were assessed via radiance imaging and overall survival.
> 
> RESULTS: Compound 991 treatment activated AMPK without limiting cellular expansion, and increased both mitochondrial density and handling of reactive oxygen species. Mechanistically, 991 treatment mimicked nutrient starvation, with increased autophagy and generation of mitochondrially protective metabolites. Importantly, receipt of 991-exposed CAR Ts significantly improved in vivo leukemia clearance and prolonged recipient survival, likely as a result of elevated activation and increased CD4+T cell yields at early times post-injection.
> 
> DISCUSSION: Ex vivo expansion is necessary to generate sufficient cell numbers for in vivo administration, but sustained activation and differentiation often negatively impact in vivo persistence and function. Here, we demonstrate that promoting AMPK activity during in vitro CAR T expansion metabolically reprograms cells without limiting T cell yield, increases early activation following in vivo transfer, and ultimately enhances anti-leukemia efficacy. Importantly, Compound 991 treatment achieves these results without further modifying the expansion media, changing the CAR T construct, or genetically altering the cells. Together, these data highlight AMPK agonism as a potent and readily translatable approach to improve the metabolic profile and in vivo efficacy of adoptively transferred T cells.

> **中文摘要：**
> 背景：嵌合抗原受体（CAR）T 细胞在临床上取得了显著成功。然而，接受 CAR T 细胞治疗的白血病患者中有多达 50% 会复发，而长期生存者的数据表明，CAR T 细胞的持久性是实现长期、无复发生存的关键。不幸的是，体外扩增方案往往会导致代谢与功能耗竭，从而降低体内效能。前临床模型已表明，重新定向代谢可改善 T 细胞在体内的功能。在此，我们假设通过暴露于靶向 AMP 激活蛋白激酶（AMPK）的激动剂，可生成在体内功能更强、对白血病清除能力更高的 CAR T 细胞。
> 
> 方法：通过慢病毒转导自健康人供体获得的 T 细胞制备 CAR T 细胞，随后分别暴露于 Compound 991 或二甲基亚砜（DMSO）96 小时。在激动剂处理期间及之后，收集 T 细胞进行代谢和功能评估。为检验体内效能，将免疫缺陷小鼠注射荧光素酶阳性的 NALM6 白血病细胞，一周后分别注射用 991 或 DMSO 扩增的 CAR T 细胞。通过光辐射成像及总体生存期评估白血病负荷及抗白血病效应。
> 
> 结果：Compound 991 处理激活了 AMPK，而未限制细胞扩增，并增加了线粒体密度及活性氧处理能力。从机制上看，991 处理模拟了营养饥饿状态，导致自噬增强并生成保护线粒体的代谢产物。重要的是，接受 991 处理的 CAR T 细胞显著改善了体内白血病清除能力并延长了受体生存期，这可能与注射后早期更高的激活水平及 CD4+ T 细胞产量增加有关。
> 
> 讨论：体外扩增是获得足够细胞数量以进行体内应用的必要步骤，但持续的激活与分化往往对体内持久性及功能造成不利影响。本研究表明，在体外 CAR T 细胞扩增过程中促进 AMPK 活性可在不限制 T 细胞产量的情况下进行代谢重编程，增强体内转移后的早期激活，最终提升抗白血病效能。值得注意的是，Compound 991 的处理无需进一步改变扩增培养基、修改 CAR T 构建或进行基因改造即可实现上述效果。总体而言，这些数据强调了 AMPK 激动作为一种强效且易于转化的方法，可改善过继转移 T 细胞的代谢特征与体内效能。

### 第二部分 AI 大师评价

本研究旨在通过 AMPK 激动剂 Compound 991 改善 CAR T 细胞在体外扩增期间的代谢状态，以增强其体内抗白血病功能。作者以健康供体 T 细胞为基础，比较了 991 与 DMSO 处理后 CAR T 的代谢与功能差异，并在小鼠模型中验证了其抗肿瘤效果。结果显示，AMPK 激活促进了线粒体活性和自噬，显著延长了小鼠生存期，且未影响细胞产量。创新点在于利用代谢重塑而非基因修饰提升 CAR T 功能，方法简便且具临床可转化潜力。研究局限在于仍属前临床阶段，需要进一步验证长期安全性与疗效。

---

## 24. TGF-βRII/IL-15免疫治疗复合物靶向淋巴结和肿瘤中的衰竭性CD8 T细胞亚群

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/41423270)
**期刊：** Journal for immunotherapy of cancer
**PMID：** 41423270
**DOI：** 10.1136/jitc-2025-013533

### 第一部分 原文与翻译

**英文原标题：** TGF-βRII/IL-15 immunotherapeutic complex targets exhausted CD8 T-cell subsets in lymph nodes and tumors.

> **英文摘要：**
> BACKGROUND: Stem-like progenitor exhausted CD8 T cells (T), located within the tumor-draining lymph nodes (TDLNs), are responsible for maintaining tumor-specific responses in cancer. Although cytokines such as interleukin (IL)-15 are known to expand CD8 T-cell subsets, transforming growth factor (TGF)-β in the TDLN is known to arrest the egress of these T to the tumor microenvironment. We hypothesized that combining IL-15 stimulatory and TGF-β blocking activity would boost antitumor responses mediated by T in the TDLN.
> 
> METHODS: We developed a bifunctional TGF-βRII/IL-15 protein complex (HCW9218) and evaluated its antitumor activity in two murine models of melanoma and breast cancer. Peripheral blood, TDLN and tumor-infiltrating CD8 T cells were characterized by flow cytometry following a single subcutaneous dose (s.c.) of HCW9218. Transcription profiling of CD8 T cells in both murine models was performed. Synergistic activity of HCW9218 with immune-checkpoint inhibitors (ICIs) was evaluated. Finally, safety and immune profiling in patients with chemo-refractory/relapsed solid tumors was performed in a Phase 1 dose-escalating trial.
> 
> RESULTS: HCW9218 was capable of localizing to the TDLNs and tumors after s.c. administration, neutralized TGF-β, expanded T in TDLNs, increased chemokine-expressing effectors in peripheral circulation and promoted their infiltration into murine tumors. These data were corroborated in RNA sequencing analysis of TDLNs. ICIs significantly enhanced the effects of HCW9218 on T and synergistically improved HCW9218 antitumor efficacy in melanoma and reduced spontaneous lung metastasis in breast cancer models. In a Phase 1 clinical trial, HCW9218 monotherapy was well-tolerated, reduced serum TGF-β levels, promoted and sustained CD8 T-cell expansion in peripheral blood and CD8 T-cell infiltration in tumor biopsies. Stable disease was reported for four of six subjects (67%) with advanced ovarian cancer treated with HCW9218.
> 
> CONCLUSIONS: Our findings demonstrate that combination therapy targeting immune cells critical for antitumor responses and blocking immune-suppressive environment significantly improves antitumor therapeutic efficacy. These findings provide a strong basis for using HCW9218 to enhance the efficacy of ICIs against solid tumors in the clinical setting.

> **中文摘要：**
> 背景：位于肿瘤引流淋巴结（TDLNs）中的干样前体衰竭性CD8 T细胞（T）负责维持肿瘤特异性免疫应答。尽管白介素（IL）-15等细胞因子已知可扩增CD8 T细胞亚群，但TDLN中的转化生长因子（TGF）-β已知会阻止这些T细胞向肿瘤微环境迁出。我们假设，将IL-15的刺激活性与TGF-β的阻断活性相结合，可增强由TDLN中的T细胞介导的抗肿瘤反应。
> 
> 方法：我们开发了一种双功能TGF-βRII/IL-15蛋白复合物（HCW9218），并在两种小鼠黑色素瘤和乳腺癌模型中评估其抗肿瘤活性。单次皮下注射（s.c.）HCW9218后，通过流式细胞术对外周血、TDLN及肿瘤浸润性CD8 T细胞进行表征。在两种小鼠模型中均进行了CD8 T细胞的转录组分析。此外，我们评估了HCW9218与免疫检查点抑制剂（ICIs）的协同效应。最后，在一项针对化疗难治性或复发性实体瘤患者的I期剂量递增试验中进行了安全性与免疫学特征分析。
> 
> 结果：皮下注射后，HCW9218能够定位至TDLN和肿瘤部位，中和TGF-β，促进TDLN内T细胞扩增，增加外周血中分泌趋化因子的效应细胞，并促进其向小鼠肿瘤浸润。RNA测序分析结果与此相符。ICI显著增强了HCW9218对T细胞的作用，并在黑色素瘤模型中协同提高其抗肿瘤效力，同时在乳腺癌模型中减轻了自发性肺转移。在I期临床试验中，HCW9218单药治疗耐受性良好，降低了血清TGF-β水平，促进并维持了外周血中CD8 T细胞的扩增及肿瘤活检组织中CD8 T细胞的浸润。在接受HCW9218治疗的6例晚期卵巢癌患者中，有4例（67%）达到疾病稳定。
> 
> 结论：我们的研究结果表明，靶向抗肿瘤免疫应答关键免疫细胞并阻断免疫抑制环境的联合治疗，可显著提高抗肿瘤治疗效果。这些发现为在临床环境下利用HCW9218增强ICIs对实体瘤的疗效提供了有力依据。

### 第二部分 AI 大师评价

本研究聚焦于一种双功能免疫治疗复合物HCW9218，该分子同时具备TGF-β阻断与IL-15刺激活性。研究者通过动物模型及I期临床试验验证其能促进抗肿瘤CD8 T细胞的扩增与浸润，且与免疫检查点抑制剂协同增强抗肿瘤效应。研究的创新点在于通过整合免疫激活与免疫抑制解除双重机制改善肿瘤微环境。局限性在于临床样本量较小，仍需进一步验证其长期疗效与安全性。

---

## 25. 癌症免疫治疗学会：多重免疫组织化学/免疫荧光检测报告标准（STORMI）

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/41423269)
**期刊：** Journal for immunotherapy of cancer
**PMID：** 41423269
**DOI：** 10.1136/jitc-2025-012280

### 第一部分 原文与翻译

**英文原标题：** Society for Immunotherapy of Cancer: Standards for Reporting of Multiplex Immunohistochemistry/Immunofluorescence Assays (STORMI).

> **英文摘要：**
> Multiplex immunofluorescence and immunohistochemistry (mIF/IHC) are increasingly employed antibody-based technologies that use tissue sparingly and facilitate the detection of co-localized or neighboring biomarkers. Specifically, these platforms enable spatial analyses of the tumor microenvironment as well as extended applications, for example, describing normal tissue anatomy, autoimmunity, infectious diseases, etc. mIF/IHC has greatly enhanced biomarker discovery efforts, and a growing number of studies suggest superiority to traditional IHC. Standardization of staining approaches, reporting of image analysis strategies and resultant data is critical for facilitating cross-study comparisons, validation, deployment, and generalization of findings. To address this challenge, The Society for Immunotherapy of Cancer (SITC) previously published two articles providing best practice guidelines for mIF/IHC staining, image analysis, and data sharing. Here, SITC convened stakeholders to develop the third article in the series, a consensus checklist for scientific reporting of mIF/IHC data to support and complement the best practice guidelines. The checklist includes critical components of mIF/IHC applications to be defined within publications such as detailed descriptions of analytical validation; image acquisition, selection, and registration methods; and cell clustering and spatial analysis strategies, amongst others. Such information will help with data reproducibility and comparison across studies towards future drug and assay development.

> **中文摘要：**
> 多重免疫荧光和免疫组织化学（mIF/IHC）是基于抗体的技术，使用较少的组织即可检测共定位或邻近的生物标志物，其应用日益广泛。具体而言，这些平台不仅可实现肿瘤微环境的空间分析，还可扩展用于描述正常组织结构、自身免疫性疾病、传染病等方面。mIF/IHC 极大地促进了生物标志物的发现研究，且越来越多的研究表明其优于传统的免疫组化。为了便于跨研究比较、验证、推广与结果普适化，对染色方法、图像分析策略及所得数据进行标准化报告至关重要。为解决这一问题，癌症免疫治疗学会（SITC）此前已发表两篇指南，提供了关于 mIF/IHC 染色、图像分析及数据共享的最佳实践建议。本文是该系列的第三篇，由 SITC 组织相关利益方共同制定了多重免疫组织化学/免疫荧光数据科学报告的共识核对清单，以支持并完善前述最佳实践指南。该清单包括需在研究发表中明确说明的 mIF/IHC 应用关键要素，比如分析验证的详细描述、图像采集、选择与配准方法，以及细胞聚类和空间分析策略等。此类信息可促进数据的可重复性和跨研究比较，为未来药物及检测方法的开发奠定基础。

### 第二部分 AI 大师评价

该文旨在制定多重免疫组织化学和免疫荧光检测的标准化报告规范，以提升数据的可重复性与跨研究的可比性。作者通过汇聚癌症免疫治疗学会（SITC）及领域专家共识，形成了一份细化的科学报告核对清单，涵盖分析验证、图像处理与空间分析等关键环节。此项工作在方法学标准化和研究透明度方面具有重要创新意义，但其实际推广仍需更多跨平台评估和国际协同验证。

---

## 26. 重组白介素-15联合纳武利尤单抗与伊匹单抗治疗难治性癌症患者的安全性、初步疗效及药效学的I期研究

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/41423268)
**期刊：** Journal for immunotherapy of cancer
**PMID：** 41423268
**DOI：** 10.1136/jitc-2025-013252

### 第一部分 原文与翻译

**英文原标题：** Phase 1 study evaluating the safety, preliminary efficacy, and pharmacodynamics of recombinant interleukin-15 in combination with nivolumab and ipilimumab in patients with refractory cancers.

> **英文摘要：**
> PURPOSE: Combinations of immune checkpoint inhibitors and cytokine therapies have shown promise in cancer immunotherapy. We aimed to evaluate the safety, tolerability, and preliminary efficacy of recombinant human interleukin-15 (rhIL-15) in combination with nivolumab and ipilimumab in patients with advanced, refractory cancers.
> 
> METHODS: This open-label, non-randomized study employed a 3+3 dose-escalation design to determine the maximum tolerated dose (MTD) of rhIL-15 combined with fixed doses of nivolumab and ipilimumab. Safety and tolerability were assessed according to Common Terminology Criteria for Adverse Events (CTCAE) criteria, and preliminary efficacy was assessed according to Response Evaluation Criteria in Solid Tumors (RECIST) and immune-related RECIST (iRECIST) criteria. Pharmacodynamic studies evaluated changes in immune cell populations in peripheral blood and paired baseline and on-treatment tumor biopsies.
> 
> RESULTS: Thirty-one patients were enrolled, with a median age of 56 years (range: 24-81 years). Five patients received rhIL-15 with either nivolumab or ipilimumab in safety run-in cohorts, 26 patients received rhIL-15 with nivolumab plus ipilimumab. The most common cancer types were gastrointestinal (n=7) or gynecologic (n=5). The MTD was 1 µg/kg/day rhIL-15, 240 mg nivolumab, and 1 mg/kg ipilimumab. The triplet combination showed a manageable safety profile; the most common treatment-related adverse events (trAEs) were chills (20/26, 77%), fever (18/26, 69%), injection site reaction (15/26, 58%), anemia (14/26, 54%), and fatigue (14/26, 54%). Lymphopenia (4/26, 15%) was the most common grade 3/4 trAE. Pharmacodynamic analysis of tumor biopsies revealed increases in CD8+, CD8+CD3ζpY142+ (ie, activated CD8+T cells), PD-1+CD3+, and CD45RO+CD3+ (ie, memory T cells) in some patients. Tumor infiltration of natural killer (NK) and γδ T cells was also observed. NK cell populations in peripheral blood were modulated by rhIL-15. 11 of 26 patients (42%) had stable disease as a best response on the triplet regimen. A partial response was measured after cycle 1 in one patient (4%) with cholangiocarcinoma and confirmed after cycle 2; this patient completed 16 cycles.
> 
> CONCLUSIONS: The combination of rhIL-15 with nivolumab and ipilimumab was safe and induced changes in immune cell populations in some patients. However, preliminary signs of efficacy were limited. Pharmacodynamic findings may support further clinical development of this combination with alternative dosing regimens or combinations of rhIL-15 with other therapeutic modalities.

> **中文摘要：**
> 目的：免疫检查点抑制剂与细胞因子疗法的联合在癌症免疫治疗中显示出潜力。本研究旨在评估重组人白介素-15（rhIL-15）联合纳武利尤单抗和伊匹单抗在晚期难治性癌症患者中的安全性、耐受性及初步疗效。
> 
> 方法：这是一项开放标签、非随机研究，采用3+3剂量递增设计以确定rhIL-15联合固定剂量纳武利尤单抗和伊匹单抗的最大耐受剂量（MTD）。安全性与耐受性根据《不良事件通用术语标准》（CTCAE）进行评估，初步疗效依据实体瘤疗效评估标准（RECIST）及免疫相关RECIST（iRECIST）进行评估。药效学研究评估外周血和基线与治疗期间配对肿瘤活检中免疫细胞群体的变化。
> 
> 结果：共入组31例患者，中位年龄56岁（范围：24–81岁）。5例患者在安全性预实验阶段接受rhIL-15联合纳武利尤单抗或伊匹单抗治疗，26例患者接受rhIL-15联合纳武利尤单抗和伊匹单抗。最常见的肿瘤类型为胃肠道（n=7）或妇科（n=5）。MTD确定为rhIL-15 1 µg/kg/日、纳武利尤单抗240 mg和伊匹单抗1 mg/kg。该三联方案的安全性可控；最常见的治疗相关不良事件（trAE）为寒战（20/26，77%）、发热（18/26，69%）、注射部位反应（15/26，58%）、贫血（14/26，54%）和疲劳（14/26，54%）。最常见的3/4级trAE为淋巴细胞减少（4/26，15%）。肿瘤活检的药效学分析显示部分患者CD8+、CD8+CD3ζpY142+（即活化CD8+T细胞）、PD-1+CD3+及CD45RO+CD3+（即记忆T细胞）细胞增加。还观察到肿瘤中自然杀伤（NK）细胞和γδ T细胞的浸润。外周血中NK细胞群体受rhIL-15调节。在接受三联方案治疗的26例患者中，11例（42%）的最佳疗效为疾病稳定；1例胆管癌患者（4%）在第1周期后出现部分缓解，并在第2周期后得到确认，该患者共完成16个治疗周期。
> 
> 结论：rhIL-15联合纳武利尤单抗和伊匹单抗的治疗方案具有良好的安全性，并在部分患者中诱导免疫细胞群体的改变。然而，初步疗效信号有限。药效学结果支持未来在不同给药方案或联合其他治疗方式下进一步开展该组合的临床研究。

### 第二部分 AI 大师评价

该研究作为I期临床试验，系统评估了重组人白介素-15与纳武利尤单抗及伊匹单抗联合治疗难治性癌症的安全性与初步疗效。结果显示该三联疗法安全性总体可控，主要不良反应为寒战、发热及注射部位反应等；药效学分析揭示了T细胞和NK细胞活化的免疫学变化。尽管部分患者表现出疾病稳定或部分缓解，但总体疗效有限。研究创新性在于探索IL-15与双免疫检查点抑制剂的联合免疫调节潜力，为未来优化给药策略或联合方案提供了依据。

---

## 27. 多组学分析揭示详细吸烟史对晚期非小细胞肺癌中免疫治疗±化疗效益的差异性影响。

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/41423267)
**期刊：** Journal for immunotherapy of cancer
**PMID：** 41423267
**DOI：** 10.1136/jitc-2025-012205

### 第一部分 原文与翻译

**英文原标题：** Multi-omics analysis reveals differential benefits of immunotherapy±chemotherapy based on detailed smoking history in advanced non-small cell lung cancer.

> **英文摘要：**
> BACKGROUND: Despite immunotherapy±chemotherapy has transformed the therapeutic landscape for patients with non-small cell lung cancer (NSCLC), critical questions remain regarding how detailed smoking history affects the evolving treatment options and the underlying molecular mechanisms driving these effects.
> 
> METHODS: We analyzed 4157 patients with advanced NSCLC who were treated with immunotherapy monotherapy (IO alone) (n=2768) or chemoimmunotherapy (chemo-IO) (n=1389) at the Dana-Farber Cancer Institute and Memorial Sloan Kettering Cancer Center (2010-2023). Associations between detailed smoking history (status and cumulative pack-years) and clinical outcomes were assessed using multivariable analyses. First-line chemo-IO versus IO alone was compared in programmed death receptor ligand 1 (PD-L1) Tumor Proportion Score (TPS) of ≥50%  wild-type patients. Tobacco smoking-related mutational signature (TSMS) was inferred from the targeted next generation sequencing (NGS) panel. We investigated relationships between detailed smoking history and tumor genomics/transcriptomics, PD-L1 expression, tumor-infiltrating lymphocytes, and circulating plasma proteomics.
> 
> RESULTS: In patients receiving IO alone, both smoking status and intensity showed dose-dependent associations with improved response and survival outcomes. In contrast, among patients receiving chemo-IO, smoking history did not affect initial response but patients with active (HR=0.73, 95% CI 0.57 to 0.94, p=0.01) and heavy tobacco use (HR=0.76, 95% CI 0.62 to 0.93, p=0.001) showed improved progression-free survival (PFS), and a trend toward improved overall survival (OS). Importantly, these associations remained independent of , , and  co-mutation status. In patients with PD-L1 TPS of ≥50% lacking  alterations, patients who do not smoke derived significant benefit from first-line chemo-IO versus IO alone with higher response rates (70.0% vs 23.9%, p=0.001), prolonged PFS (median PFS 9.5 vs 3.7 months, HR=0.51, 95% CI 0.27 to 0.95, p=0.04), and a trend toward prolonged OS, while patients who smoke showed comparable outcomes with either strategy. TSMS independently predicted improved outcomes of IO alone, even after tumor mutational burden (TMB) adjustment. Molecular analyses revealed associations between tobacco use and higher TMB, increased tumor-infiltrating lymphocytes (CD8, PD-1, CD8PD-1, FOXP3) and distinct plasma protein profiles involved in immune signaling pathways (CCL7, CXCL17, CDCP1, TNFRSF6B).
> 
> CONCLUSIONS: Detailed smoking history provides crucial insights for optimizing IO selection in advanced NSCLC through mechanistic alterations in both the tumor microenvironment and systemic plasma protein profiles.

> **中文摘要：**
> 背景：尽管免疫治疗±化疗已改变非小细胞肺癌（NSCLC）患者的治疗格局，但关于详细吸烟史如何影响不断发展的治疗选择及其潜在分子机制仍存在关键问题。
> 
> 方法：我们分析了来自达纳-法伯癌症研究所和纪念斯隆凯特琳癌症中心的4157例晚期NSCLC患者（2010–2023年），他们接受了免疫治疗单药（IO单药，n=2768）或免疫化疗联合（chemo-IO，n=1389）。通过多变量分析评估详细吸烟史（吸烟状态及累计包年数）与临床结局之间的关系。在程序性死亡配体1（PD-L1）肿瘤比例评分（TPS）≥50%的野生型患者中，比较了一线chemo-IO与IO单药的效果。通过靶向下一代测序（NGS）推断烟草吸烟相关突变特征（TSMS）。我们进一步探讨了吸烟史与肿瘤基因组/转录组学、PD-L1表达、肿瘤浸润淋巴细胞以及外周血浆蛋白质组学之间的关系。
> 
> 结果：在接受IO单药治疗的患者中，吸烟状态和吸烟强度与改善的疗效及生存结果呈剂量依赖性关联。相比之下，在接受chemo-IO治疗的患者中，吸烟史未影响初始反应，但活跃吸烟者（HR=0.73，95% CI 0.57–0.94，p=0.01）和重度吸烟者（HR=0.76，95% CI 0.62–0.93，p=0.001）具有更长的无进展生存期（PFS），并呈现总体生存期（OS）改善趋势。重要的是，这些相关性独立于共突变状态。在PD-L1 TPS ≥50%且无特定基因改变的患者中，不吸烟者相比IO单药从一线chemo-IO中获得显著获益，包括更高的应答率（70.0% vs 23.9%，p=0.001）、更长的PFS（中位PFS 9.5 vs 3.7个月，HR=0.51，95% CI 0.27–0.95，p=0.04）以及OS延长趋势；而吸烟者在两种策略下的结局相当。TSMS在调整肿瘤突变负荷（TMB）后仍能独立预测IO单药的更优结局。分子分析显示，吸烟与更高的TMB、升高的肿瘤浸润淋巴细胞（CD8、PD-1、CD8PD-1、FOXP3）及涉及免疫信号通路的差异性血浆蛋白（CCL7、CXCL17、CDCP1、TNFRSF6B）相关。
> 
> 结论：详细吸烟史通过对肿瘤微环境和系统性血浆蛋白特征的机制性改变，为优化晚期NSCLC的免疫治疗选择提供了关键见解。

### 第二部分 AI 大师评价

该研究通过对4157例晚期非小细胞肺癌患者的多组学数据分析，系统揭示了吸烟史在免疫治疗和免疫化疗疗效差异中的关键作用。研究发现，吸烟强度与免疫单药疗效呈剂量依赖关系，而不吸烟者在PD-L1高表达人群中更受益于联合化疗。该研究的创新在于结合临床数据与多组学特征，阐明了吸烟相关免疫调控机制。其局限在于回顾性设计及部分基因信息缺失，但为个体化免疫策略提供了有价值的方向。

---

## 28. 依托泊苷通过肿瘤分泌的 IL-33 介导信号上调 MHC I，从而激活骨肉瘤中 CD8 T 细胞的抗肿瘤免疫反应

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/41423266)
**期刊：** Journal for immunotherapy of cancer
**PMID：** 41423266
**DOI：** 10.1136/jitc-2025-012591

### 第一部分 原文与翻译

**英文原标题：** Etoposide activates CD8 T cell anti-tumor immunity in osteosarcoma through MHC I upregulation via tumor-secreted IL-33 mediated signaling.

> **英文摘要：**
> BACKGROUND: Osteosarcoma patients with high propensity for metastasis and recurrence generally encounter a poor prognosis. Despite the extensive exploration of immunotherapy, particularly the anti-programmed cell death protein 1 (anti-PD-1) antibody, in clinical trials, the efficacy remains unsatisfactory. A more profound comprehension of the resistance mechanisms and the development of innovative therapeutic strategies is imperative.
> 
> METHODS: A screening was performed for drugs capable of upregulating major histocompatibility class I (MHC I) expression among clinically common drugs. The effects of the drug on both T cells and tumor cells, as well as its combination efficacy with anti-PD-1 antibody, were studied in vitro and in vivo osteosarcoma models. The molecular mechanisms underlying these biological processes were explored via RNA sequencing analysis.
> 
> RESULTS: Etoposide was shown to upregulate the MHC I expression in osteosarcoma cells, thereby enhancing the cytotoxicity of CD8 T cells. Interleukin-33 (IL-33) played a dominant role in etoposide-activated anti-tumor immune response. Etoposide promoted the secretion of IL-33 and augmented the expression of IL-33 binding suppression of tumorigenicity 2 (ST2) receptor, which activated the nuclear factor kappa-B signaling pathway and resulted in MHC I upregulation. Furthermore, etoposide was demonstrated to improve the therapeutic efficacy of anti-PD-1 antibody.
> 
> CONCLUSIONS: This study revealed the molecular mechanism underlying etoposide-activated CD8 T cell anti-tumor immunity. The combination of Etoposide and anti-PD-1 antibody has the potential to benefit patients with advanced osteosarcoma.

> **中文摘要：**
> 背景：具有高转移和复发倾向的骨肉瘤患者通常预后不良。尽管在临床试验中广泛探索了免疫治疗，尤其是抗程序性细胞死亡蛋白1（anti-PD-1）抗体，但疗效仍不理想。迫切需要更深入理解耐药机制，并开发创新的治疗策略。
> 
> 方法：对临床常用药物进行筛选，寻找能够上调主要组织相容性复合体I类（MHC I）表达的药物。在体内和体外骨肉瘤模型中研究该药物对T细胞及肿瘤细胞的作用，以及其与anti-PD-1抗体联合应用的效果。通过RNA测序分析探索这些生物学过程的分子机制。
> 
> 结果：研究发现，依托泊苷可上调骨肉瘤细胞中MHC I的表达，从而增强CD8 T细胞的细胞毒活性。白介素-33（IL-33）在依托泊苷激活的抗肿瘤免疫应答中起主要作用。依托泊苷促进IL-33的分泌，并增强其结合受体ST2（抑瘤因子2）的表达，从而激活核因子κB信号通路，最终导致MHC I上调。此外，依托泊苷被证实可提高anti-PD-1抗体的治疗效果。
> 
> 结论：本研究揭示了依托泊苷激活CD8 T细胞抗肿瘤免疫的分子机制。依托泊苷联合anti-PD-1抗体有望为晚期骨肉瘤患者提供获益。

### 第二部分 AI 大师评价

该研究旨在阐明依托泊苷增强骨肉瘤免疫治疗反应的分子机制。研究者通过筛选药物上调MHC I表达，发现依托泊苷可激活IL-33/ST2/NF-κB通路，从而增强CD8 T细胞介导的抗肿瘤免疫，并改善anti-PD-1抗体疗效。该研究具有较强的机制探索深度和潜在转化价值，但仍需在更大样本和临床验证中进一步确认其安全性与可行性。

---

## 29. 抗HER2×CCR4双特异性抗体通过阻断趋化并清除肿瘤相关调节性T细胞，在晚期HER2阳性肿瘤中增强抗肿瘤免疫而不引发系统性毒性。

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/41423265)
**期刊：** Journal for immunotherapy of cancer
**PMID：** 41423265
**DOI：** 10.1136/jitc-2025-012829

### 第一部分 原文与翻译

**英文原标题：** Anti-HER2×CCR4 bispecific antibody enhances antitumor immunity in advanced HER2-positive tumors by chemotaxis blockade and depletion of tumor-associated Tregs, without inducing systemic toxicity.

> **英文摘要：**
> BACKGROUND: CCR4 regulatory T cells (Tregs), which are widely present in peripheral circulation and tumor microenvironment (TME), promote tumor immune evasion by infiltrating human epidermal growth factor receptor 2-positive (HER2) tumors in a chemokine-driven manner. However, therapies targeting CCR4 (eg, mogamulizumab) for systemic Treg depletion risk significant toxicity and have far been confined to hematological malignancies. Notably, tumor-chemotactic peripheral Tregs-key precursors to tumor-infiltrating Tregs (tumor-infiltrating lymphocyte (TIL)-Tregs)-remain overlooked.
> 
> METHODS: We designed and expressed four candidate anti-HER2×CCR4 DVD-Ig bispecific antibodies with varying degrees of anti-CCR4 domain masking, while leaving anti-HER2 domains fully exposed, to preferentially deplete tumor-associated Tregs, including TIL-Tregs and tumor-chemotactic peripheral Tregs. Stability and antitumor activity were assessed in vitro. In human immune system-reconstituted NOG mice, we systematically: (1) conducted a comprehensive dose-response evaluation of the XL-11 to characterize pharmacological efficacy and potential systemic toxicity, (2) assessed the immune memory, (3) studied the synergy of XL-11 with programmed cell death protein-1/programmed death-ligand 1 (PD-1/L1) blocker, and (4) analyzed pharmacokinetic profile (PK).
> 
> RESULTS: The lower affinity for CCR4 compared with HER2 enables anti-HER2×CCR4 DVD-Igs to priority target TIL-Tregs, and reduce binding to peripheral Tregs compared with mogamulizumab. Anti-HER2×CCR4 DVD-Igs inhibit Treg chemotaxis to TME, and killing Tregs and HER2 tumor cells through antibody-dependent cellular cytotoxicity. Among the candidates, XL-11, which had the greatest exposure of the anti-CCR4 domain, was selected for in vivo evaluation due to its superior stability and potent antitumor activity. In vivo models of gastric cancer and breast cancer, XL-11, by reducing TIL-Tregs and increasing CD8/Tregs ratios, induces potent antitumor activity even in advanced stages, with no evidence of metastasis. Concurrently, XL-11 specifically depletes tumor-chemotactic peripheral Tregs, further enhancing antitumor immunity while avoiding reducing Tregs throughout the body even at a high dose (10 mg/kg). There was no increase in memory T cells. In addition, XL-11 enhances the antitumor activity of anti-PD-1 antibodies and shows superior PK properties.
> 
> CONCLUSIONS: XL-11 mediates potent antitumor immunity in advanced HER2 tumors while avoiding reducing Tregs throughout the body. XL-11 also acts synergistically with anti-PD-1 therapy, and exhibits favorable stability and PK supporting clinical translation. This work advances Treg-targeted therapies in HER2 tumors and overcomes the therapeutic limitations of mogamulizumab.

> **中文摘要：**
> 背景：CCR4调节性T细胞（Treg）广泛存在于外周循环和肿瘤微环境（TME）中，通过趋化因子驱动的方式浸润人表皮生长因子受体2阳性（HER2）肿瘤，促进肿瘤的免疫逃逸。然而，靶向CCR4的治疗（如mogamulizumab）用于系统性Treg清除时存在显著毒性风险，目前主要局限于血液系统恶性肿瘤。值得注意的是，具肿瘤趋化性的外周Treg——肿瘤浸润性Treg （肿瘤浸润性淋巴细胞，TIL-Treg）的关键前体——迄今仍被忽视。
> 
> 方法：我们设计并表达了四种候选抗HER2×CCR4 DVD-Ig双特异性抗体，其抗CCR4结构域遮蔽程度不同，而抗HER2结构域保持完全暴露，以优先清除肿瘤相关Treg，包括TIL-Treg和具肿瘤趋化性的外周Treg。通过体外实验评估稳定性和抗肿瘤活性。在人免疫系统重建的NOG小鼠中，我们系统地：（1）进行了XL-11的剂量反应综合评估，以表征药理效力及潜在的系统性毒性；（2）评估免疫记忆；（3）研究XL-11与程序性细胞死亡蛋白1/其配体（PD-1/L1）阻断剂的协同效应；（4）分析其药代动力学特征（PK）。
> 
> 结果：由于其对CCR4的亲和力低于HER2，抗HER2×CCR4 DVD-Ig能够优先靶向TIL-Treg，并较mogamulizumab减少对外周Treg的结合。抗HER2×CCR4 DVD-Ig通过抗体依赖的细胞毒作用抑制Treg向TME的趋化，并杀伤Treg和HER2肿瘤细胞。在候选分子中，因抗CCR4结构域暴露度最高，XL-11表现出优异的稳定性和强效的抗肿瘤活性，被选用于体内研究。在胃癌和乳腺癌模型中，XL-11通过减少TIL-Treg并提高CD8/Treg比值，在晚期阶段仍能诱导显著的抗肿瘤效应，且未见转移证据。同时，XL-11选择性清除具肿瘤趋化性的外周Treg，进一步增强抗肿瘤免疫，同时即使在高剂量（10 mg/kg）下也未导致全身Treg减少。此外，未见记忆T细胞数量增加。另有研究发现，XL-11可增强抗PD-1抗体的抗肿瘤效应，并表现出优越的药代特征。
> 
> 结论：XL-11在晚期HER2肿瘤中能够介导强效的抗肿瘤免疫，同时避免全身性Treg减少。XL-11还可与抗PD-1治疗协同作用，并具有良好的稳定性和药代动力学特征，支持其临床转化。本研究推动了HER2肿瘤中Treg靶向治疗的发展，并克服了mogamulizumab的治疗局限性。

### 第二部分 AI 大师评价

本研究针对HER2阳性肿瘤中调节性T细胞导致的免疫逃逸，创新性地设计了抗HER2×CCR4双特异性抗体以实现肿瘤局部的Treg选择性清除。通过结构优化与人源化模型验证，研究发现XL-11在增强抗肿瘤免疫的同时避免了系统性毒性。其与抗PD-1疗法的协同效果、优越的药代及安全特性凸显了临床应用潜力。总体上，该研究为克服传统CCR4抗体毒性限制并优化Treg靶向免疫治疗提供了新策略，但仍需在人类临床中验证长期疗效与安全性。

---

## 30. TIPE2缺失可增强巨噬细胞对肿瘤细胞的吞噬作用

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/41423264)
**期刊：** Journal for immunotherapy of cancer
**PMID：** 41423264
**DOI：** 10.1136/jitc-2025-013425

### 第一部分 原文与翻译

**英文原标题：** TIPE2 deficiency enhances macrophage phagocytosis of tumor cells.

> **英文摘要：**
> INTRODUCTION: Understanding the negative regulatory mechanisms of immune cell functions is essential for developing effective tumor immunotherapy strategies. Macrophages play a crucial role in antitumor immunity; however, the mechanisms that negatively regulate their antitumor functions remain incompletely understood. TIPE2 is known to be a critical regulator of various immune cells, but its role as a negative regulator of macrophage antitumor functions has not yet been established.
> 
> OBJECTIVES: This study aims to investigate whether TIPE2 negatively regulates the antitumor functions of macrophages and to elucidate the mechanisms involved.
> 
> METHODS: We used a mouse model of hepatic tumor metastasis and a subcutaneous tumor model to evaluate the impact of TIPE2 on macrophage antitumor functions. In vitro experiments, including fluorescence microscopy and flow cytometry, were conducted to assess whether the TIPE2 deficiency enhances the phagocytic activity of macrophages against tumor cells. Additionally, we employed co-immunoprecipitation assays along with spleen tyrosine kinase (SYK) and Ras-related C3 botulinum toxin substrate 1 (RAC1) signaling blockade assays to investigate the molecular mechanisms through which TIPE2 exerts its negative regulatory effects.
> 
> RESULTS: Our findings indicate that TIPE2 gene loss in myeloid cells inhibits hepatic tumor metastasis, which is dependent on macrophages in the liver. Furthermore, macrophages lacking TIPE2 demonstrated enhanced tumor growth inhibition in subcutaneous tumor models. In vitro, these macrophages exhibited increased phagocytic activity against tumor cells. Mechanistically, TIPE2 negatively regulates the activation of SYK and RAC1, thereby modulating the phagocytic capabilities of macrophages.
> 
> CONCLUSION: TIPE2 represents a negative regulatory mechanism for macrophage phagocytosis against tumor cells. In the future, TIPE2 may serve as a promising target to enhance the efficacy of tumor immunotherapy strategies based on macrophages.

> **中文摘要：**
> 引言：理解免疫细胞功能的负向调控机制对于开发有效的肿瘤免疫治疗策略至关重要。巨噬细胞在抗肿瘤免疫中发挥关键作用；然而，其抗肿瘤功能的负向调控机制尚未完全阐明。TIPE2已被证实是多种免疫细胞的重要调节因子，但其作为巨噬细胞抗肿瘤功能的负性调控因子的角色尚未建立。
> 
> 研究目的：本研究旨在探讨TIPE2是否负向调控巨噬细胞的抗肿瘤功能，并阐明其相关机制。
> 
> 方法：研究者采用小鼠肝转移瘤模型和皮下肿瘤模型评估TIPE2对巨噬细胞抗肿瘤功能的影响。体外实验包括荧光显微镜和流式细胞术，用以评估TIPE2缺失是否增强巨噬细胞对肿瘤细胞的吞噬活性。此外，研究还利用共免疫沉淀实验以及脾酪氨酸激酶（SYK）与Ras相关的C3肉毒毒素底物1（RAC1）信号阻断实验，探讨TIPE2发挥负向调控作用的分子机制。
> 
> 结果：研究发现髓系细胞中TIPE2基因缺失可抑制肝脏肿瘤转移，该效应依赖于肝内巨噬细胞。此外，缺失TIPE2的巨噬细胞在皮下肿瘤模型中表现出更强的肿瘤生长抑制能力。体外实验显示，这些巨噬细胞对肿瘤细胞具有增强的吞噬活性。在机制层面，TIPE2通过负向调控SYK和RAC1的活化，从而调节巨噬细胞的吞噬能力。
> 
> 结论：TIPE2构成了巨噬细胞对肿瘤细胞吞噬作用的负性调控机制。未来，TIPE2可能成为基于巨噬细胞的肿瘤免疫治疗策略中具有潜力的增强靶点。

### 第二部分 AI 大师评价

本研究系统揭示了TIPE2作为巨噬细胞抗肿瘤功能负调控因子的作用。研究者通过体内外模型证实TIPE2缺失可增强巨噬细胞对肿瘤细胞的吞噬活性，并阐明了SYK和RAC1信号通路在其中的分子机制。该研究为改善基于巨噬细胞的肿瘤免疫治疗提供了新靶点，创新性体现在明确了TIPE2的负调控角色。其局限性在于研究主要集中于小鼠模型，未来需在临床层面进一步验证其可行性与安全性。

---

## 31. 可解释的多模态放射病理组学模型用于预测食管鳞状细胞癌新辅助化疗免疫治疗的病理完全缓解

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/41423263)
**期刊：** Journal for immunotherapy of cancer
**PMID：** 41423263
**DOI：** 10.1136/jitc-2025-013840

### 第一部分 原文与翻译

**英文原标题：** Interpretable multimodal radiopathomics model predicting pathological complete response to neoadjuvant chemoimmunotherapy in esophageal squamous cell carcinoma.

> **英文摘要：**
> BACKGROUND: Accurate preoperative prediction of pathological complete response (pCR) following neoadjuvant chemoimmunotherapy (nCIT) could help individualize treatment for patients with esophageal squamous cell carcinoma (ESCC). This study aimed to develop and externally validate an interpretable multimodal machine learning framework that integrates CT radiomics and H&E-stained whole-slide images pathomics to predict pCR.
> 
> METHODS: In this multicenter, retrospective study, 335 patients with ESCC who received nCIT followed by esophagectomy were enrolled from three institutions. Patients from one center were divided into a training set (181 patients) and an internal test set (115 patients), while data from the other two centers comprised an external test set (39 patients). We developed unimodal radiomics and pathomics models, and two multimodal fusion models-an intermediate fusion model (MIFM) and a late fusion model (MLFM). Model performance was evaluated using the area under the curve (AUC), accuracy, sensitivity, specificity, and F1 score, with exploratory survival stratification by observed and model-predicted pCR status. Interpretability was treated as a design constraint and operationalized at both the feature and model levels.
> 
> RESULTS: The MIFM outperformed unimodal models and the MLFM across all cohorts, achieving AUC/accuracy/sensitivity/specificity/F1 score of 0.97/0.93/0.84/0.96/0.86 (training set), 0.78/0.87/0.62/0.93/0.63 (internal test set), and 0.76/0.77/0.54/0.88/0.61 (external test set). Both observed and predicted pCR status showed exploratory prognostic stratification for overall survival. Feature definitions were mathematically or morphologically explicit, and case-level/cohort-level explanations together with decision-pathway views provided insights into model reasoning. We additionally provide a user-friendly Graphical User Interface to facilitate clinical practice.
> 
> CONCLUSIONS: We developed and externally validated an interpretable radiopathomics fusion framework that predicts pCR after nCIT in ESCC using standard-of-care data. This model holds promise as an effective tool for guiding individualized decisions between surveillance and timely surgery.

> **中文摘要：**
> 背景：准确预测食管鳞状细胞癌（ESCC）患者在接受新辅助化疗免疫治疗（nCIT）后的病理完全缓解（pCR），可帮助实现个体化治疗。本研究旨在开发并外部验证一种可解释的多模态机器学习框架，该框架整合CT影像组学与H&E染色全切片图像的病理组学，用于预测pCR。
> 
> 方法：这项多中心回顾性研究共纳入来自三家机构的335例接受nCIT及后续食管切除术的ESCC患者。来自一个中心的患者被随机分为训练集（181例）和内部测试集（115例），其余两个中心的数据组成外部测试集（39例）。研究构建了单模态影像组学和病理组学模型，以及两种多模态融合模型——中间融合模型（MIFM）和后期融合模型（MLFM）。通过曲线下面积（AUC）、准确率、敏感性、特异性及F1得分评价模型性能，并进行了基于观察到的及模型预测的pCR状态的探索性生存分层分析。可解释性作为设计约束，在特征层面和模型层面均得到实现。
> 
> 结果：在所有队列中，MIFM均优于单模态模型和MLFM。其在训练集、内部测试集及外部测试集中的AUC/准确率/敏感性/特异性/F1得分分别为0.97/0.93/0.84/0.96/0.86，0.78/0.87/0.62/0.93/0.63，及0.76/0.77/0.54/0.88/0.61。观察到的及预测的pCR状态在总体生存方面均显示出探索性的预后分层价值。特征定义在数学或形态学上均具有明确性，结合个案级和队列级解释及决策路径展示，为模型推理提供了洞察。此外，还开发了用户友好的图形界面以便于临床应用。
> 
> 结论：本研究开发并外部验证了一种可解释的放射病理组学融合框架，利用常规医疗数据预测ESCC患者nCIT后的pCR情况。该模型有望成为指导个体化监测与及时手术决策的有效工具。

### 第二部分 AI 大师评价

本研究针对新辅助化疗免疫治疗后食管鳞癌的病理完全缓解预测，构建了一个可解释的多模态放射病理组学机器学习模型。研究通过整合CT影像特征与病理切片组学，实现了多层次特征融合，并在三中心数据中得到内部与外部验证。结果显示，中间融合模型在预测性能上优于单模态及晚期融合模型，并具备良好的生存分层能力。创新之处在于模型的可解释性设计与可视化界面支持，但其回顾性和样本量限制提示未来需进一步前瞻性验证。

---

## 32. 更正：《微波激活的细菌生物机器人用于多模态癌症治疗》

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/41422477)
**期刊：** Advanced science (Weinheim, Baden-Wurttemberg, Germany)
**PMID：** 41422477
**DOI：** 10.1002/advs.202520958

### 第一部分 原文与翻译

**英文原标题：** Correction to "Microwave-Activated Bacterial Biorobot for Multimodal Cancer Therapy".

> **英文摘要：**
> No abstract available.

> **中文摘要：**
> 无可用摘要。

### 第二部分 AI 大师评价

本条目为对先前发表于《Advanced Science》的原始论文《微波激活的细菌生物机器人用于多模态癌症治疗》的更正说明。更正类文章通常涉及数据、图表或方法学内容的修订，旨在维护科研透明度与结果的准确性。虽然未提供摘要，但此类更正体现了作者和期刊对科研严谨性的重视，有助于提升后续研究的可靠性。

---

## 33. CD168标识小鼠和人胰岛中增殖的胰岛细胞

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/41422437)
**期刊：** Advanced science (Weinheim, Baden-Wurttemberg, Germany)
**PMID：** 41422437
**DOI：** 10.1002/advs.202510590

### 第一部分 原文与翻译

**英文原标题：** CD168 Identifies Proliferating Pancreatic Islet Cells in Murine and Human.

> **英文摘要：**
> Restoring functional β-cell mass through proliferation is a central goal of diabetes therapy, but progress has been hampered by the inability to isolate live, proliferating β-cells for study. Here, CD168 is identified as a conserved surface marker that specifically enriches for proliferating cells in mouse and human pancreatic islets. Single-cell RNA sequencing reveals a distinct cluster of islet cells with high proliferative activity, low insulin expression, and specific CD168 expression. Flow cytometry and immunostaining confirm CD168 cells co-localize with Ki67 proliferating cells, reside in G2/M phase, and comprise ≈0.5% of adult islet cells. Using a new CD168-CreERT2 mouse model for lineage tracing, it is demonstrated that CD168⁺ cells rapidly divide, forming two-cell clones within hours. Unbiased lineage tracing shows 87.4% of clones are uni-β lineage, with smaller proportions of uni-α, uni-δ, and multi-lineage. Integrated lineage tracing with multi-omics maps a ≈60-day maturation trajectory for nascent β-cells, involving progressive epigenome remodeling and shifting transcriptional networks. Notably, CD168 expression is conserved in proliferating cells of human islets and pancreatic neuroendocrine tumors, highlighting its clinical relevance. This work establishes CD168 as a marker for proliferating islet cells, providing a tool to study β-cell proliferation and novel insights into islet cell proliferation and maturation mechanisms.

> **中文摘要：**
> 通过促进β细胞增殖来恢复其功能性质量，是糖尿病治疗的核心目标，但由于无法分离活的、正在增殖的β细胞进行研究，这一领域的进展受到了限制。在本研究中，CD168被鉴定为一种保守的细胞表面标志物，能够在小鼠和人胰岛中特异性富集增殖细胞。单细胞RNA测序揭示了一个具有高增殖活性、低胰岛素表达和特异性CD168表达的胰岛细胞簇。流式细胞术和免疫染色结果证实，CD168阳性细胞与Ki67阳性增殖细胞共定位，处于G2/M期，占成年胰岛细胞的约0.5%。利用新的CD168-CreERT2小鼠谱系追踪模型，研究显示CD168⁺细胞迅速分裂，并在数小时内形成双细胞克隆。无偏谱系追踪表明，87.4%的克隆为单β系谱，较小比例的克隆为单α、单δ及多系谱类型。整合谱系追踪与多组学分析绘制出新生β细胞约60天的成熟轨迹，过程中涉及逐步的表观基因组重塑和转录网络变化。值得注意的是，CD168的表达在人体胰岛和胰腺神经内分泌肿瘤的增殖细胞中保持保守，凸显其临床相关性。本研究建立了CD168作为胰岛增殖细胞标志物的地位，为研究β细胞增殖及胰岛细胞增殖与成熟机制提供了新工具和新见解。

### 第二部分 AI 大师评价

该研究旨在解决糖尿病研究中难以分离活性增殖β细胞的关键障碍，通过发现CD168这一保守的表面标志物，实现了对小鼠和人胰岛增殖细胞的特异性识别。研究采用单细胞测序、流式细胞术及谱系追踪等多种技术，系统揭示了CD168⁺细胞的增殖特征、谱系分化及成熟轨迹。结果不仅确认了CD168的生物学功能和保守性，还提出其在胰腺肿瘤学中的潜在意义。该工作具有显著的创新性，在分子标志物层面为β细胞增殖研究提供了实验工具，但仍需进一步验证其在人类胰岛修复中的功能应用。

---

## 34. 通过ADP-核糖环化酶合成双特异性偶联物

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/41422434)
**期刊：** Advanced science (Weinheim, Baden-Wurttemberg, Germany)
**PMID：** 41422434
**DOI：** 10.1002/advs.202518329

### 第一部分 原文与翻译

**英文原标题：** Synthesis of Bispecific Conjugates by ADP-Ribosyl Cyclases.

> **英文摘要：**
> Armed with two distinct targeting moieties, artificially created bispecific agents can uniquely modulate various processes and events implicated in human health and diseases. Despite recent approvals of multiple bispecific therapeutics, generation of homogeneous dual-targeting constructs with desired pharmacological properties remains technically challenging. Here, we report a strategy for synthesis of bispecific agents by utilizing CD38, a member of the ADP-ribosyl cyclase family, and its covalent inhibitor. A model ADP-ribosyl cyclase-enabled bispecific conjugate (ARC-BsC) against human T-cell CD3 and prostate-specific membrane antigen (PSMA) is generated through site-specific conjugation of an anti-CD3 antibody-CD38 fusion with the CD38 covalent inhibitor derivatized by a PSMA small-molecule ligand. The resulting ARC-BsC can redirect and activate cytotoxic T cells toward killing PSMA-expressing tumor cells, eliciting highly potent and selective anti-cancer immunity in vitro and in vivo. This proof-of-concept work demonstrates ARC-BsC as a potentially general approach for the development of bispecific therapeutics with diverse applications.

> **中文摘要：**
> 人工构建的双特异性分子同时具备两种不同的靶向基团，能够独特地调控与人类健康和疾病相关的多种生物过程与事件。尽管近年来已有多种双特异性治疗药物获批，但制备具备理想药理特性的均一双靶构型仍存在技术挑战。本文报道了一种利用ADP-核糖环化酶家族成员CD38及其共价抑制剂合成双特异性分子的策略。研究者以人T细胞受体CD3和前列腺特异性膜抗原（PSMA）为靶点，通过将抗CD3抗体–CD38融合蛋白与经PSMA小分子配体修饰的CD38共价抑制剂进行特定位点偶联，构建出一种模型ADP-核糖环化酶介导的双特异性偶联物（ARC-BsC）。所得ARC-BsC能够重定向并激活细胞毒性T细胞，以杀伤表达PSMA的肿瘤细胞，从而在体内外诱导出强效且选择性的抗癌免疫反应。本研究的概念验证性成果表明，ARC-BsC有望成为开发多种应用领域双特异性治疗药物的一种通用策略。

### 第二部分 AI 大师评价

该研究旨在开发一种利用ADP-核糖环化酶催化机制的新型双特异性偶联物合成策略。通过以CD38及其共价抑制剂构建桥梁，实现了抗体与小分子靶向配体的精准偶联，生成具有针对CD3与PSMA双重靶向能力的ARC-BsC。结果显示，该偶联物可有效引导T细胞特异性杀伤肿瘤细胞，展现出显著的抗癌效能。该方法的创新之处在于将酶媒介偶联机制应用于双特异性药物构建，为未来个性化免疫治疗提供了新的设计路径，但仍需在药代特性和生产工艺稳定性方面进一步验证。

---

速递结束，祝您工作愉快！